

Fundamental Mechanisms of Immune Checkpoint Block

Cancer Discovery

8, 1069-1086

DOI: [10.1158/2159-8290.cd-18-0367](https://doi.org/10.1158/2159-8290.cd-18-0367)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The growing role of precision and personalized medicine for cancer treatment. <i>Technology</i> , 2018, 06, 79-100.	1.4	237
2	Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 3081.	2.2	116
3	Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity. <i>Frontiers in Immunology</i> , 2018, 9, 2810.	2.2	80
4	Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018, 155, 1684-1686.	0.6	4
5	Evaluation of anti-inflammatory and immunomodulatory effects of <i>Premna integrifolia</i> extracts and assay-guided isolation of a COX-2/5-LOX dual inhibitor. <i>FÄ-toterapÄ-Äç</i> , 2018, 131, 189-199.	1.1	19
6	Bioactive Nanoparticles for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3877.	1.8	82
7	Experimental and investigational drugs for the treatment of anal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 941-950.	1.9	4
8	Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8 ⁺ T cell dysfunction and maintain memory phenotype. <i>Science Immunology</i> , 2018, 3, .	5.6	133
9	Developing combination immunotherapies against cancer that make sense. <i>Science Immunology</i> , 2018, 3, .	5.6	7
10	Macrophage Checkpoint Blockade in Cancer â€” Back to the Future. <i>New England Journal of Medicine</i> , 2018, 379, 1777-1779.	13.9	39
11	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <i>Autoimmunity</i> , 2019, 52, 144-160.	1.2	10
12	On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment. <i>Chemotherapy</i> , 2019, 64, 62-80.	0.8	34
13	Obesity and Breast Cancer: Role of Leptin. <i>Frontiers in Oncology</i> , 2019, 9, 596.	1.3	175
14	Inducible Tâ€cell coâ€stimulator: Signaling mechanisms in T follicular helper cells and beyond. <i>Immunological Reviews</i> , 2019, 291, 91-103.	2.8	37
15	Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination. <i>Frontiers in Oncology</i> , 2019, 9, 811.	1.3	47
16	USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity. <i>Cancer Immunology Research</i> , 2019, 7, 1580-1590.	1.6	94
17	Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. <i>Frontiers in Immunology</i> , 2019, 10, 1848.	2.2	56
18	ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. <i>Molecular Therapy</i> , 2019, 27, 1878-1891.	3.7	38

#	ARTICLE	IF	CITATIONS
19	Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. <i>Physiological Reviews</i> , 2019, 99, 1765-1817.	13.1	550
20	Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies. <i>Frontiers in Immunology</i> , 2019, 10, 1791.	2.2	19
21	Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. <i>Clinical Chemistry</i> , 2019, 65, 1228-1238.	1.5	178
22	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. <i>Cancer Cell</i> , 2019, 36, 168-178.e4.	7.7	240
23	Oncolytic Viruses: Priming Time for Cancer Immunotherapy. <i>BioDrugs</i> , 2019, 33, 485-501.	2.2	90
24	Establishment of syngeneic murine model for oral cancer therapy. <i>Oral Oncology</i> , 2019, 95, 194-201.	0.8	19
25	Decoding the PTM-switchboard of Notch. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 118507.	1.9	25
26	Immunotherapeutic Approaches in Cancer Treatment. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 204-205.	0.9	1
27	Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation. <i>Immunity</i> , 2019, 51, 15-26.	6.6	143
28	Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1654.	2.2	101
29	Toward Normalization of the Tumor Microenvironment for Cancer Therapy. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541986235.	0.8	27
30	Integrative Approaches to Cancer Immunotherapy. <i>Trends in Cancer</i> , 2019, 5, 400-410.	3.8	64
31	Low-dose nivolumab induced durable complete response in relapsed primary central nervous system diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 2227-2230.	0.8	8
32	AP-1 Transcription Factors as Regulators of Immune Responses in Cancer. <i>Cancers</i> , 2019, 11, 1037.	1.7	166
33	Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 537-544.	0.6	18
34	Metabolic flexibility in melanoma: A potential therapeutic target. <i>Seminars in Cancer Biology</i> , 2019, 59, 187-207.	4.3	62
35	Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer. <i>Scientific Reports</i> , 2019, 9, 10918.	1.6	27
36	Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 861.	1.7	25

#	ARTICLE	IF	CITATIONS
37	Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. <i>Oncotarget</i> , 2019, 10, 3835-3839.	0.8	8
38	Determinants of immunological evasion and immuncheckpoint inhibition response in non-small cell lung cancer: the genetic front. <i>Oncogene</i> , 2019, 38, 5921-5932.	2.6	27
39	Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy. <i>Biophysical Chemistry</i> , 2019, 253, 106213.	1.5	22
40	Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. <i>Cell Research</i> , 2019, 29, 609-627.	5.7	74
41	YAP and TAZ: a signalling hub of the tumour microenvironment. <i>Nature Reviews Cancer</i> , 2019, 19, 454-464.	12.8	252
42	Cutaneous Metastasis after Surgery, Injury, Lymphadenopathy, and Peritonitis: Possible Mechanisms. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3286.	1.8	11
43	Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. <i>Scientific Reports</i> , 2019, 9, 15099.	1.6	40
44	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1247-1263.	1.4	29
45	Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum?. <i>Molecular Therapy</i> , 2019, 27, 1874-1877.	3.7	0
46	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3021-3036.	1.2	20
47	Contribution of Fc γ 3 receptor IIB to creating a suppressive tumor microenvironment in a mouse model. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1769-1778.	2.0	5
48	HTLV-1 as a Model for Virus and Host Coordinated Immunoediting. <i>Frontiers in Immunology</i> , 2019, 10, 2259.	2.2	6
49	A mouse model-based screening platform for the identification of immune activating compounds such as natural products for novel cancer immunotherapies. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115145.	1.4	4
50	Immune-Based Therapies in Acute Leukemia. <i>Trends in Cancer</i> , 2019, 5, 604-618.	3.8	32
51	SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling. <i>Frontiers in Immunology</i> , 2019, 10, 2468.	2.2	37
52	Noninvasive imaging in cancer immunotherapy: The way to precision medicine. <i>Cancer Letters</i> , 2019, 466, 13-22.	3.2	19
53	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. <i>Cancer Immunology Research</i> , 2019, 7, 1910-1927.	1.6	74
54	Three decades of messenger RNA vaccine development. <i>Nano Today</i> , 2019, 28, 100766.	6.2	177

#	ARTICLE	IF	CITATIONS
55	NKG2D Controls Natural Reactivity of VÎ³9VÎ²2 T Lymphocytes against Mesenchymal Glioblastoma Cells. <i>Clinical Cancer Research</i> , 2019, 25, 7218-7228.	3.2	28
56	Theranostics in immuno-oncology using nanobody derivatives. <i>Theranostics</i> , 2019, 9, 7772-7791.	4.6	83
57	VEGF-A drives TOX-dependent T cell exhaustion in antiâ€“PD-1â€“resistant microsatellite stable colorectal cancers. <i>Science Immunology</i> , 2019, 4, .	5.6	148
58	Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. <i>Theranostics</i> , 2019, 9, 7906-7923.	4.6	100
59	Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. <i>Nature Communications</i> , 2019, 10, 4869.	5.8	36
60	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3484-3492.	0.8	30
61	Microenvironmental Heterogeneity in Brain Malignancies. <i>Frontiers in Immunology</i> , 2019, 10, 2294.	2.2	78
62	Exploiting NK Cell Surveillance Pathways for Cancer Therapy. <i>Cancers</i> , 2019, 11, 55.	1.7	41
63	Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 158.	1.8	29
64	Combination antiâ€“CTLA-4 plus antiâ€“PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22699-22709.	3.3	226
65	Novel Biomarkers for Personalized Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1223.	1.7	36
66	Phagocytosis checkpoints as new targets for cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 568-586.	12.8	557
67	New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4136.	1.8	249
68	Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis. <i>EBioMedicine</i> , 2019, 47, 78-88.	2.7	24
69	Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6995-7003.	3.2	70
70	Concurrent therapy with immune checkpoint inhibitors and TNFÎ± blockade in patients with gastrointestinal immune-related adverse events. , 2019, 7, 226.		89
71	Engineered nanoparticles circumvent the adaptive treatment tolerance to immune-checkpoint blockade therapy. <i>Science China Chemistry</i> , 2019, 62, 1557-1560.	4.2	5
72	NK Cell Dysfunction and Checkpoint Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1999.	2.2	105

#	ARTICLE	IF	CITATIONS
73	Can Allosteric Receptor-Protein Interactions in Receptor Complexes Be a Molecular Mechanism Involved in Cancer Immune Therapy?. <i>Frontiers in Endocrinology</i> , 2019, 10, 574.	1.5	1
74	Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. , 2019, 7, 239.		81
75	Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1585-1596.	2.0	37
76	Immunotherapy for Lymphangioliomyomatosis and Tuberous Sclerosis. <i>Chest</i> , 2019, 156, 1062-1067.	0.4	15
77	Pre-surgical oncolytic virotherapy improves breast cancer outcomes. <i>Oncolmunology</i> , 2019, 8, e1655363.	2.1	4
78	Immunobiology of cholangiocarcinoma. <i>JHEP Reports</i> , 2019, 1, 297-311.	2.6	79
79	The Good, The Bad, and The Unexpected: Roles of DUX4 in Health and Disease. <i>Developmental Cell</i> , 2019, 50, 525-526.	3.1	3
80	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>Oncolmunology</i> , 2019, 8, e1657375.	2.1	56
81	Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. <i>Nature Protocols</i> , 2019, 14, 2900-2930.	5.5	92
82	Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1547.	1.0	30
83	Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. <i>Biomolecules</i> , 2019, 9, 548.	1.8	43
84	GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. <i>Cell Reports</i> , 2019, 28, 3367-3380.e8.	2.9	37
85	Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 690-704.	8.2	686
86	Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. <i>Oncolmunology</i> , 2019, 8, e1659096.	2.1	26
87	Clinical significance and prospective molecular mechanism of C&C motif chemokine receptors in patients with early&stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. <i>Oncology Reports</i> , 2019, 42, 1856-1868.	1.2	4
88	Nivolumab plus Ipilimumab in Advanced Non&Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2020-2031.	13.9	1,866
89	Past, Current, and Future of Immunotherapies for Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 884.	1.3	89
90	Immune Checkpoint Inhibitor Therapy&related Pneumonitis: Patterns and Management. <i>Radiographics</i> , 2019, 39, 1923-1937.	1.4	109

#	ARTICLE	IF	CITATIONS
91	SnapShot: Cancer Immunotherapy with Oncolytic Viruses. <i>Cell</i> , 2019, 176, 1240-1240.e1.	13.5	50
92	Double Immune Checkpoint Blockade in Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2019, 3, 163-170.	0.2	1
93	The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2019, 11, 140.	1.7	18
94	Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 14.	1.3	33
95	Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment. <i>Processes</i> , 2019, 7, 37.	1.3	115
96	SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. <i>EBioMedicine</i> , 2019, 40, 151-162.	2.7	53
97	Negative regulation of innate lymphoid cell responses in inflammation and cancer. <i>Immunology Letters</i> , 2019, 215, 28-34.	1.1	10
98	Epigenetic therapy in immune-oncology. <i>Nature Reviews Cancer</i> , 2019, 19, 151-161.	12.8	345
99	Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms. <i>Translational Oncology</i> , 2019, 12, 987-995.	1.7	32
100	Crystal Structure of the Fab Fragment of an Anti-CTLA-4 Antibody, Ipilimumab, Used for Cancer Immunotherapy. <i>Bulletin of the Korean Chemical Society</i> , 2019, 40, 582-585.	1.0	0
101	Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-6.	0.5	33
102	Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 498.	1.3	33
103	Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches. <i>Advances in Cancer Research</i> , 2019, 144, 193-261.	1.9	19
104	Metastasis as a systemic disease: molecular insights and clinical implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 89-102.	3.3	44
105	Tumour-associated macrophages in hepatocellular carcinoma: Pressing the metabolic switch to prevent T cell responses. <i>Journal of Hepatology</i> , 2019, 71, 243-245.	1.8	4
106	Î³ T cells: pleiotropic immune effectors with therapeutic potential in cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 392-404.	12.8	255
107	Thermal ablation and systemic therapies in the metastatic liver: time for a "global" approach. <i>European Radiology</i> , 2019, 29, 5042-5044.	2.3	2
108	Antiproliferative Activity of Chemically Characterized Propolis from Turkey and Its Mechanisms of Action. <i>Chemistry and Biodiversity</i> , 2019, 16, e1900189.	1.0	25

#	ARTICLE	IF	CITATIONS
109	Targeting the Tumor Microenvironment of Leukemia and Lymphoma. Trends in Cancer, 2019, 5, 351-364.	3.8	67
110	Type I interferons and dendritic cells in cancer immunotherapy. International Review of Cell and Molecular Biology, 2019, 348, 217-262.	1.6	81
111	Towards Immunotherapy for Pediatric Brain Tumors. Trends in Immunology, 2019, 40, 748-761.	2.9	77
112	Functional genomics in cancer immunotherapy: computational approaches for biomarker and drug discovery. Molecular Systems Design and Engineering, 2019, 4, 689-700.	1.7	3
113	TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 731-741.	1.8	193
114	lluminating the Onco-GPCRome: Novel G protein-coupled receptor-driven onocrine networks and targets for cancer immunotherapy. Journal of Biological Chemistry, 2019, 294, 11062-11086.	1.6	129
115	Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports. International Journal of Molecular Sciences, 2019, 20, 2578.	1.8	31
116	Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors. JAMA Oncology, 2019, 5, 999.	3.4	47
117	Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chemical Society Reviews, 2019, 48, 3771-3810.	18.7	292
118	Immunology and Immunotherapy in Critical Care: An Overview. AACN Advanced Critical Care, 2019, 30, 113-125.	0.6	6
119	Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion. Cancer Research, 2019, 79, 3903-3915.	0.4	68
120	In vitro assessment of PD-L1+ microvesicles in the cyst fluid of non-syndromic odontogenic keratocysts. Journal of Molecular Histology, 2019, 50, 325-333.	1.0	3
121	CD81 is a novel immunotherapeutic target for B cell lymphoma. Journal of Experimental Medicine, 2019, 216, 1497-1508.	4.2	31
122	Dysbiosis of the Gut Microbiome in Lung Cancer. Frontiers in Cellular and Infection Microbiology, 2019, 9, 112.	1.8	138
123	Contribution of Epithelial Plasticity to Therapy Resistance. Journal of Clinical Medicine, 2019, 8, 676.	1.0	42
124	Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes. Cancers, 2019, 11, 682.	1.7	10
125	Regulatory Immune Mechanisms beyond Regulatory T Cells. Trends in Immunology, 2019, 40, 482-491.	2.9	38
126	Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically. Cancer Immunology Research, 2019, 7, 1064-1078.	1.6	104

#	ARTICLE	IF	CITATIONS
127	Treatment of Metastatic Disease through Natural Killer Cell Modulation by Infected Cell Vaccines. <i>Viruses</i> , 2019, 11, 434.	1.5	4
128	Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1018-1027.	2.3	15
129	Obsessive compulsive disorder (OCD): Current treatments and a framework for neurotherapeutic research. <i>Advances in Pharmacology</i> , 2019, 86, 237-271.	1.2	5
130	Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 628.	1.7	51
131	LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling. <i>Frontiers in Immunology</i> , 2019, 10, 1159.	2.2	58
132	Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy. <i>Journal of Proteome Research</i> , 2019, 18, 2666-2675.	1.8	22
133	Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 178-189.	2.0	31
134	Immunometabolism: A new target for improving cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 195-253.	1.9	30
135	Construction of small molecular CTLA4 analogs with CD80-binding affinity. <i>Biochemical and Biophysical Research Communications</i> , 2019, 513, 694-700.	1.0	4
136	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. <i>Clinical Cancer Research</i> , 2019, 25, 5743-5751.	3.2	129
137	Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 33-51.	3.0	115
138	Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. , 2019, 7, 105.		103
139	3D models in the new era of immune oncology: focus on T cells, CAF and ECM. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 117.	3.5	78
140	Innate lymphoid cells: A potential link between microbiota and immune responses against cancer. <i>Seminars in Immunology</i> , 2019, 41, 101271.	2.7	13
141	Ubiquitin Ligases in Cancer Immunotherapy – Balancing Antitumor and Autoimmunity. <i>Trends in Molecular Medicine</i> , 2019, 25, 428-443.	3.5	35
142	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 361-375.	8.2	1,039
143	Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma. <i>Oncolmmunology</i> , 2019, 8, e1577108.	2.1	35
144	Immunological and clinical implications of immune checkpoint blockade in human cancer. <i>Archives of Pharmacal Research</i> , 2019, 42, 567-581.	2.7	17

#	ARTICLE	IF	CITATIONS
145	Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies. <i>Neurology</i> , 2019, 92, 663-674.	1.5	115
146	Cancer-associated fibroblasts: how do they contribute to metastasis?. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 71-86.	1.7	93
147	Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy. <i>Cancer Letters</i> , 2019, 452, 51-58.	3.2	16
148	Resolving genetic heterogeneity in cancer. <i>Nature Reviews Genetics</i> , 2019, 20, 404-416.	7.7	443
149	Treg programming and therapeutic reprogramming in cancer. <i>Immunology</i> , 2019, 157, 198-209.	2.0	46
150	Targeting Tumor-Associated Macrophages in Cancer. <i>Trends in Immunology</i> , 2019, 40, 310-327.	2.9	660
151	Combined Inhibition of TGF- β 2 Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. <i>Cells</i> , 2019, 8, 320.	1.8	82
152	The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. , 2019, 7, 103.		79
153	Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. <i>Molecules</i> , 2019, 24, 1190.	1.7	163
154	Immunology's Coming of Age. <i>Frontiers in Immunology</i> , 2019, 10, 684.	2.2	73
155	A PD-1-specific toxin suppresses autoimmunity. <i>Nature Biomedical Engineering</i> , 2019, 3, 253-254.	11.6	7
156	Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. , 2019, 7, 52.		43
157	T cell checkpoint regulators in the heart. <i>Cardiovascular Research</i> , 2019, 115, 869-877.	1.8	70
158	Fc γ 3R-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 292.	2.2	111
159	Virus-Based Immunotherapy of Glioblastoma. <i>Cancers</i> , 2019, 11, 186.	1.7	107
160	Innate Immune Modulation by GM-CSF and IL-3 in Health and Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 834.	1.8	48
161	Immunotherapy and targeted therapy combinations in metastatic breast cancer. <i>Lancet Oncology</i> , The, 2019, 20, e175-e186.	5.1	329
162	T Cell-Redirecting Strategies to α -STAb TM Tumors: Beyond CARs and Bispecific Antibodies. <i>Trends in Immunology</i> , 2019, 40, 243-257.	2.9	32

#	ARTICLE	IF	CITATIONS
163	PAS-MUT with Somatic Mutations in Cancer and Classified Diseases for Clinical-Genomics Research: PAS-MUT & Somatic Mutations. , 2019, , .		0
164	Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. <i>Current Breast Cancer Reports</i> , 2019, 11, 248-258.	0.5	2
165	From Super-Enhancer Non-coding RNA to Immune Checkpoint: Frameworks to Functions. <i>Frontiers in Oncology</i> , 2019, 9, 1307.	1.3	29
166	Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1798.	1.7	99
167	PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. <i>Immunity</i> , 2019, 51, 1059-1073.e9.	6.6	229
168	Cutaneous and Pulmonary Sarcoid-Like Reaction Induced by Nivolumab. <i>Journal of Clinical Rheumatology</i> , 2021, 27, S460-S464.	0.5	7
169	Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer. <i>Scientific Data</i> , 2019, 6, 323.	2.4	39
170	Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment. <i>Clinical Cancer Research</i> , 2019, 25, 7243-7255.	3.2	57
171	A Case of Severe Seronegative Inflammatory Arthritis due to Nivolumab and Review of the Literature. <i>Case Reports in Rheumatology</i> , 2019, 2019, 1-9.	0.2	2
172	Delivery strategies of cancer immunotherapy: recent advances and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 126.	6.9	96
173	The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers. <i>Journal of Cancer</i> , 2019, 10, 5992-6002.	1.2	22
174	Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient. , 2019, 7, 336.		21
175	Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-“Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, 535-543.	0.7	48
176	Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology. <i>Current Opinion in Urology</i> , 2019, 29, 521-525.	0.9	5
177	Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications. <i>Cell Communication and Signaling</i> , 2019, 17, 172.	2.7	46
178	A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2. <i>Cell Reports</i> , 2019, 29, 3435-3447.e4.	2.9	33
179	Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 381-398.	1.2	54
180	Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. <i>Current Opinion in Neurology</i> , 2019, 32, 500-510.	1.8	57

#	ARTICLE	IF	CITATIONS
181	Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. <i>Nature Communications</i> , 2019, 10, 5546.	5.8	98
182	Enforcing the checkpoints. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 213-218.	1.2	25
183	Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. <i>Rheumatology</i> , 2019, 58, vii68-vii74.	0.9	31
184	Memory T cell exhaustion and tolerance in transplantation. <i>Immunological Reviews</i> , 2019, 292, 225-242.	2.8	18
185	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27
186	Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. <i>Rheumatology</i> , 2019, 58, vii59-vii67.	0.9	137
187	The Roles of Hypoxia-Inducible Factors and Non-Coding RNAs in Gastrointestinal Cancer. <i>Genes</i> , 2019, 10, 1008.	1.0	14
188	Immune Checkpoint Blockade – How Does It Work in Brain Metastases?. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 282.	1.4	25
189	Immunotherapies for pediatric cancer: current landscape and future perspectives. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 573-594.	2.7	20
190	Improving the Design of Synthetic Oligonucleotide Probes by Fluorescence Melting Assay. <i>ChemBioChem</i> , 2019, 20, 587-594.	1.3	13
191	Role of miRNAs in immune responses and immunotherapy in cancer. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 244-253.	1.5	105
192	Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 105-115.	0.9	16
193	Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. <i>Cancer Science</i> , 2019, 110, 489-498.	1.7	66
194	Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board. <i>Trends in Immunology</i> , 2019, 40, 83-85.	2.9	37
195	H19X-encoded miR-424(322)/-503 cluster: emerging roles in cell differentiation, proliferation, plasticity and metabolism. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 903-920.	2.4	54
196	The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2019, 40, 142-158.	2.9	218
197	Analysis for Science Librarians of the 2018 Nobel Prize in Physiology or Medicine: The Life and Work of James P. Allison and Tasuku Honjo. <i>Science and Technology Libraries</i> , 2019, 38, 1-29.	0.8	0
198	CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. <i>Cancer Cell International</i> , 2019, 19, 12.	1.8	46

#	ARTICLE	IF	CITATIONS
199	Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. , 2019, 7, 6.		190
200	An emerging role for nanomaterials in increasing immunogenicity of cancer cell death. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 99-108.	3.3	41
201	Antibody therapeutics and immunoregulation in cancer and autoimmune disease. <i>Seminars in Cancer Biology</i> , 2020, 64, 1-12.	4.3	93
202	CD8 ⁺ T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion. <i>Leukemia and Lymphoma</i> , 2020, 61, 351-356.	0.6	17
203	Diversity, Mechanisms, and Significance of Macrophage Plasticity. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 123-147.	9.6	932
204	Brain Metastasis Organotropism. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037242.	2.9	26
205	Tumour-intrinsic resistance to immune checkpoint blockade. <i>Nature Reviews Immunology</i> , 2020, 20, 25-39.	10.6	856
206	Radiologic Imaging of Bowel Infections. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 33-45.	0.7	8
207	Angioedema late in the course of adjuvant nivolumab therapy for melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1019-1021.	0.5	6
208	Hepatic Arterial Bland Embolization Increases Th17 Cell Infiltration in a Syngeneic Rat Model of Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 311-321.	0.9	15
209	Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1-12.	4.8	273
210	Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. <i>Seminars in Cancer Biology</i> , 2020, 64, 93-101.	4.3	135
211	Immune checkpoints in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2020, 65, 1-12.	4.3	146
212	4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 955-971.	3.6	70
213	PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 243-250.	1.4	16
214	Translational pathology, genomics and the development of systemic therapies for acral melanoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 149-157.	4.3	30
215	TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity. <i>Oncolmmunology</i> , 2020, 9, 1681869.	2.1	14
216	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2020, 16, 4439-4453.	1.1	29

#	ARTICLE	IF	CITATIONS
217	Galactoxyloglucan Endowed Biogenic Nanoimmunobiotics Arrests Microbial Growth and Elicits Antitumor Immunity. <i>ACS Applied Bio Materials</i> , 2020, 3, 801-814.	2.3	7
218	Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. <i>Clinical Cancer Research</i> , 2020, 26, 679-689.	3.2	49
219	Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 140-154.	4.3	66
221	Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100166.	0.7	23
222	Tumor microenvironment differences between primary tumor and brain metastases. <i>Journal of Translational Medicine</i> , 2020, 18, 1.	1.8	532
224	Vessel co-option and resistance to anti-angiogenic therapy. <i>Angiogenesis</i> , 2020, 23, 55-74.	3.7	77
225	Tumor intrinsic and extrinsic immune functions of CD155. <i>Seminars in Cancer Biology</i> , 2020, 65, 189-196.	4.3	85
226	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	4.3	9
227	¹⁸ F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors. <i>PET Clinics</i> , 2020, 15, 11-22.	1.5	22
228	Role of Radiation in the Era of Effective Systemic Therapy for Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 189-199.	0.5	6
229	Molecular imaging biomarkers for immune checkpoint inhibitor therapy. <i>Theranostics</i> , 2020, 10, 1708-1718.	4.6	68
230	The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer. <i>Mutagenesis</i> , 2020, 35, 69-78.	1.0	1
231	WNT and β -Catenin in Cancer: Genes and Therapy. <i>Annual Review of Cancer Biology</i> , 2020, 4, 177-196.	2.3	39
232	Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 43-55.	2.0	56
233	Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes. <i>Cancer Treatment Reviews</i> , 2020, 84, 101950.	3.4	19
234	Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 4-12.	4.0	82
235	Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, e484-e491.	1.9	29
236	Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival. <i>Autoimmunity Reviews</i> , 2020, 19, 102456.	2.5	12

#	ARTICLE	IF	CITATIONS
237	The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap. <i>Pharmacological Reviews</i> , 2020, 72, 80-151.	7.1	29
238	Optimizing immunotherapy for gynecologic cancers. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 1-8.	0.9	27
239	Biomarkers that may predict response to immunotherapy in ovarian malignancies. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 84-90.	0.9	8
240	Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma. <i>Cancer Treatment Reviews</i> , 2020, 82, 101931.	3.4	33
241	Biomaterials as Tools to Decode Immunity. <i>Advanced Materials</i> , 2020, 32, e1903367.	11.1	36
243	Promising approaches in cancer immunotherapy. <i>Immunobiology</i> , 2020, 225, 151875.	0.8	49
244	Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. <i>Current Opinion in Oncology</i> , 2020, 32, 106-113.	1.1	52
245	Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA). <i>Cancers</i> , 2020, 12, 37.	1.7	179
246	CAR T-Cell Therapy for CNS Malignancies. , 2020, , 165-198.		0
247	Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade. <i>Medicine (United States)</i> , 2020, 99, e22153.	0.4	7
248	Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 291-298.	0.7	21
249	m ⁶ A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. <i>EMBO Journal</i> , 2020, 39, e104514.	3.5	229
250	Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2020, 11, 2105.	2.2	164
251	Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy. , 2020, 8, e001222.		60
252	Recent Advances in Nanomaterial-Assisted Combinational Sonodynamic Cancer Therapy. <i>Advanced Materials</i> , 2020, 32, e2003214.	11.1	333
253	Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics. <i>Accounts of Chemical Research</i> , 2020, 53, 2521-2533.	7.6	81
254	Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. <i>Nature Medicine</i> , 2020, 26, 1865-1877.	15.2	62
255	Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 589641.	2.2	21

#	ARTICLE	IF	CITATIONS
256	DNA Damage and Cancer Immunotherapy: A STING in the Tale. <i>Molecular Cell</i> , 2020, 80, 21-28.	4.5	161
257	Therapy of Primary Liver Cancer. <i>Innovation(China)</i> , 2020, 1, 100032.	5.2	46
258	Self-Adjuvanting Cancer Vaccines from Conjugation-Ready Lipid A Analogues and Synthetic Long Peptides. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11691-11706.	2.9	28
259	Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 576310.	2.2	23
260	Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	142
262	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
263	Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. <i>Nature Communications</i> , 2020, 11, 5332.	5.8	15
264	Immune receptor inhibition through enforced phosphatase recruitment. <i>Nature</i> , 2020, 586, 779-784.	13.7	59
265	Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7621.	1.8	12
266	Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7743.	1.8	36
267	Irreversible electroporation plus allogenic $\hat{V}^{\hat{3}}\hat{9}\hat{V}^{\hat{2}}$ T cells enhances antitumor effect for locally advanced pancreatic cancer patients. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 215.	7.1	54
268	Impact of anatomic site on antigen-presenting cells in cancer. , 2020, 8, e001204.		10
269	CNOT4 enhances the efficacy of anti- $\hat{P}\hat{D}\hat{1}$ immunotherapy in a model of non- \hat{e} small cell lung cancer. <i>FEBS Open Bio</i> , 2020, 10, 2631-2639.	1.0	3
270	Severe delayed pulmonary toxicity following $\hat{P}\hat{D}\hat{1}$ -specific CAR \hat{T} cell therapy for non- \hat{e} small cell lung cancer. <i>Clinical and Translational Immunology</i> , 2020, 9, e1154.	1.7	12
271	Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. , 2020, 8, e001437.		57
272	A gene expression signature of TREM2hi macrophages and $\hat{1}^{\hat{3}}$ T cells predicts immunotherapy response. <i>Nature Communications</i> , 2020, 11, 5084.	5.8	90
273	Partial Least-Squares Discriminant Analysis and Ensemble-Based Flexible Docking of PD-1/PD-L1 Inhibitors: A Pilot Study. <i>ACS Omega</i> , 2020, 5, 26914-26923.	1.6	7
274	Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma. <i>Journal of Cancer</i> , 2020, 11, 6516-6529.	1.2	9

#	ARTICLE	IF	CITATIONS
275	Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation. <i>Frontiers in Oncology</i> , 2020, 10, 1785.	1.3	35
276	Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. <i>Cytotherapy</i> , 2020, 22, 204-213.	0.3	9
277	Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive \hat{I}^2 Cell Destruction. <i>Cell Reports Medicine</i> , 2020, 1, 100097.	3.3	16
278	Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy. <i>Oncologist</i> , 2020, 25, 1009-1012.	1.9	10
279	Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis. <i>IScience</i> , 2020, 23, 101499.	1.9	33
280	The Paradoxical Roles of Inflammation during PD-1 Blockade in Cancer. <i>Trends in Immunology</i> , 2020, 41, 982-993.	2.9	19
281	Targeting the HIF2 \hat{e} -VEGF axis in renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 1519-1530.	15.2	248
282	Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 ⁺ and CD4 ⁺ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. , 2020, 8, e000605.		34
283	Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4878.	1.8	25
284	Natural products and their derivatives: Promising modulators of tumor immunotherapy. <i>Journal of Leukocyte Biology</i> , 2020, 108, 493-508.	1.5	114
285	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 663.	2.0	24
286	QSP \hat{e} : A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno \hat{e} Oncology Applications. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 484-497.	1.3	34
287	Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy. <i>Medicine in Drug Discovery</i> , 2020, 8, 100073.	2.3	10
288	SOCS, Intrinsic Virulence Factors, and Treatment of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 582102.	2.2	31
289	A narrative review of toxicity of chemoradiation and immunotherapy for unresectable, locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2040-2050.	1.3	6
290	Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting. <i>JACC: CardioOncology</i> , 2020, 2, 491-502.	1.7	20
291	Development and validation of a prognostic and immunotherapeutically relevant model in hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1177-1177.	0.7	8
292	Applications of Single-Cell Omics to Dissect Tumor Microenvironment. <i>Frontiers in Genetics</i> , 2020, 11, 548719.	1.1	18

#	ARTICLE	IF	CITATIONS
293	Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. <i>Vaccines</i> , 2020, 8, 708.	2.1	13
294	Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 607-623.	2.4	10
295	Mechanical Immunoengineering of T cells for Therapeutic Applications. <i>Accounts of Chemical Research</i> , 2020, 53, 2777-2790.	7.6	24
296	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. <i>Frontiers in Oncology</i> , 2020, 10, 590058.	1.3	5
297	Cutaneous melanoma and the immunotherapy revolution (Review). <i>International Journal of Oncology</i> , 2020, 57, 609-618.	1.4	75
298	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (donâ€™t) know. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 236.	3.5	44
299	Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies. <i>Seminars in Oncology</i> , 2020, 47, 367-379.	0.8	6
300	Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. <i>Communications Biology</i> , 2020, 3, 720.	2.0	82
301	New viral vectors for infectious diseases and cancer. <i>Seminars in Immunology</i> , 2020, 50, 101430.	2.7	55
302	Emerging impact of the long noncoding RNA MIR22HG on proliferation and apoptosis in multiple human cancers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 271.	3.5	56
303	Clinical value of CTLA4 combined with clinicopathological factors in evaluating the prognosis of breast cancer. <i>Gland Surgery</i> , 2020, 9, 1328-1337.	0.5	5
304	Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment. <i>Pan African Medical Journal</i> , 2020, 36, 309.	0.3	7
305	Modelling of Immune Checkpoint Network Explains Synergistic Effects of Combined Immune Checkpoint Inhibitor Therapy and the Impact of Cytokines in Patient Response. <i>Cancers</i> , 2020, 12, 3600.	1.7	9
306	Evolving impact of long-term survival results on metastatic melanoma treatment. , 2020, 8, e000948.		59
307	Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2020, 2020, 1-13.	0.9	76
308	Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors. <i>Scientific Reports</i> , 2020, 10, 19296.	1.6	39
309	Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8305.	1.8	58
310	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 36.	1.0	26

#	ARTICLE	IF	CITATIONS
311	PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. , 2020, 8, e001631.		44
312	Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. Journal of Clinical Medicine, 2020, 9, 2533.	1.0	15
313	Dissecting genetic determinants of variation in human immune responses. Current Opinion in Immunology, 2020, 65, 74-78.	2.4	3
314	Antitumor immunity and T-cell avidity. Blood, 2020, 136, 378-380.	0.6	2
315	Integrating the microbiome into the barrier theory of cancer. Evolutionary Applications, 2020, 13, 1701-1707.	1.5	4
316	A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications. Frontiers in Immunology, 2020, 11, 1612.	2.2	21
317	Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment. Cellular and Molecular Immunology, 2020, 17, 940-953.	4.8	41
318	Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions. Cancers, 2020, 12, 2005.	1.7	18
319	An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells. Cell, 2020, 182, 1009-1026.e29.	13.5	194
320	PD-L1 Expression Affects Neoantigen Presentation. IScience, 2020, 23, 101238.	1.9	9
321	Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell, 2020, 38, 473-488.	7.7	342
322	Adoptive T Cell Therapy with IL-12â€œPreconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity. Journal of Immunology, 2020, 205, 1449-1460.	0.4	20
323	Failure Mode and Effects Analysis (FMEA) for Immunogenicity of Therapeutic Proteins. Journal of Pharmaceutical Sciences, 2020, 109, 3214-3222.	1.6	2
324	The immunology of renal cell carcinoma. Nature Reviews Nephrology, 2020, 16, 721-735.	4.1	229
325	Immunological combination treatment holds the key to improving survival in pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2897-2911.	1.2	14
326	Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Leukemia, 2020, 34, 3413-3419.	3.3	42
327	Cell and tissue engineering in lymph nodes for cancer immunotherapy. Advanced Drug Delivery Reviews, 2020, 161-162, 42-62.	6.6	43
328	Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. Journal of the Endocrine Society, 2020, 4, bvaa069.	0.1	14

#	ARTICLE	IF	CITATIONS
329	Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature. <i>Journal of Immunotherapy</i> , 2020, 43, 224-229.	1.2	5
330	Targeting immune checkpoints in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2020, 13, 111.	6.9	66
331	Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells. <i>Cancers</i> , 2020, 12, 2204.	1.7	12
332	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2020, 10, 1842-1853.	7.7	179
333	Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. <i>BMC Cancer</i> , 2020, 20, 760.	1.1	43
334	Bone metastasis is associated with acquisition of mesenchymal phenotype and immune suppression in a model of spontaneous breast cancer metastasis. <i>Scientific Reports</i> , 2020, 10, 13838.	1.6	23
335	Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. <i>Immunotherapy</i> , 2020, 12, 1213-1219.	1.0	6
336	Natural Killer T-Cell Agonist Î±-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 581301.	2.2	21
337	The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study. <i>Frontiers in Immunology</i> , 2020, 11, 524968.	2.2	7
338	Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions. <i>Journal of Biological Chemistry</i> , 2020, 295, 18036-18050.	1.6	16
339	Pan-TGFÎ² inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. <i>Onc Immunology</i> , 2020, 9, 1811605.	2.1	30
340	Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy. , 2020, 8, e001247.		18
342	Focal adhesion ribonucleoprotein complex proteins are major humoral cancer antigens and targets in autoimmune diseases. <i>Communications Biology</i> , 2020, 3, 588.	2.0	4
343	Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma. , 2020, 8, e001202.		29
344	Taming the Sentinels: Microbiome-Derived Metabolites and Polarization of T Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7740.	1.8	12
345	Impact of checkpoint blockade on cancer vaccineâ€activated CD8+ T cell responses. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	20
346	Layilin augments integrin activation to promote antitumor immunity. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	28
347	Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching. <i>Cancers</i> , 2020, 12, 2429.	1.7	5

#	ARTICLE	IF	CITATIONS
348	Emerging connectivity of programmed cell death pathways and its physiological implications. <i>Nature Reviews Molecular Cell Biology</i> , 2020, 21, 678-695.	16.1	465
349	iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. <i>Polymers</i> , 2020, 12, 1906.	2.0	45
350	Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. <i>Cancers</i> , 2020, 12, 2447.	1.7	70
351	A Tumor-Immune Interaction Model for Synergistic Combinations of Anti PD-L1 and Ionizing Irradiation Treatment. <i>Pharmaceutics</i> , 2020, 12, 830.	2.0	8
352	AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. <i>Blood Advances</i> , 2020, 4, 4180-4194.	2.5	29
353	Leukotrienes in Tumor-Associated Inflammation. <i>Frontiers in Pharmacology</i> , 2020, 11, 1289.	1.6	45
354	Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 2020, 11, 1842.	2.2	28
355	PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. <i>Nature Communications</i> , 2020, 11, 4835.	5.8	290
356	Targeting TANK-binding kinase 1 (TBK1) in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1065-1078.	1.5	26
357	Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy. <i>Biomaterials</i> , 2020, 263, 120380.	5.7	11
358	Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. <i>Cancer Cell</i> , 2020, 38, 454-472.	7.7	190
359	Cardiothoracic Complications of Immune Checkpoint Inhibitor Therapy: An Imaging Review. <i>Journal of Computer Assisted Tomography</i> , 2020, 44, 652-655.	0.5	2
360	Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2935.	1.0	8
361	Immune Related Adverse Events. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 432-440.	1.0	4
362	Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent. <i>Scientific Reports</i> , 2020, 10, 12772.	1.6	5
363	An update on the immune landscape in lung and head and neck cancers. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 505-517.	157.7	93
364	Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 819-822.	1.1	6
365	Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 116.	1.8	9

#	ARTICLE	IF	CITATIONS
366	Upregulated expression of LncRNA nicotinamide nucleotide transhydrogenase antisense RNA 1 is correlated with unfavorable clinical outcomes in cancers. <i>BMC Cancer</i> , 2020, 20, 879.	1.1	4
367	Breaking Bottlenecks for the TCR Therapy of Cancer. <i>Cells</i> , 2020, 9, 2095.	1.8	35
368	Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response. <i>Nature Cancer</i> , 2020, 1, 923-934.	5.7	67
369	Chimeric antigen receptor T cell therapies for thoracic cancers—challenges and opportunities. <i>Journal of Thoracic Disease</i> , 2020, 12, 4510-4515.	0.6	1
370	Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 2626.	1.7	26
371	Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma. <i>JAAD Case Reports</i> , 2020, 6, 819-821.	0.4	2
372	Discovery and Optimization of Small-Molecule Ligands for V-Domain Ig Suppressor of T-Cell Activation (VISTA). <i>Journal of the American Chemical Society</i> , 2020, 142, 16194-16198.	6.6	19
373	Predictive values of colon microbiota in the treatment response to colorectal cancer. <i>Pharmacogenomics</i> , 2020, 21, 1045-1059.	0.6	4
374	Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives. <i>Cancers</i> , 2020, 12, 2334.	1.7	15
375	Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. , 2020, 8, e000964.		15
376	Applications of organoids for cancer biology and precision medicine. <i>Nature Cancer</i> , 2020, 1, 761-773.	5.7	93
377	Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin's lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 27, 107815522097679.	0.5	6
378	3D Tumor Models and Their Use for the Testing of Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 603640.	2.2	90
379	Autophagy protects tumors from T cell-mediated cytotoxicity via inhibition of TNF-induced apoptosis. <i>Science Immunology</i> , 2020, 5, .	5.6	63
380	PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages. <i>Frontiers in Immunology</i> , 2020, 11, 588552.	2.2	80
381	Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators. <i>Cancers</i> , 2020, 12, 3773.	1.7	33
382	Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. <i>Cancers</i> , 2020, 12, 3851.	1.7	27
383	PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 475.	1.8	23

#	ARTICLE	IF	CITATIONS
384	The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices. <i>Frontiers in Neuroscience</i> , 2020, 14, 603647.	1.4	24
385	Immune gene therapy of cancer. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1679-1690.	0.4	9
387	Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression. <i>Oncoimmunology</i> , 2020, 9, 1851950.	2.1	8
388	Emerging nanomedicines for effective breast cancer immunotherapy. <i>Journal of Nanobiotechnology</i> , 2020, 18, 180.	4.2	46
389	Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients. <i>American Journal of Roentgenology</i> , 2021, 217, 613-622.	1.0	9
390	TGF- β 2 Mediated Immune Evasion in Cancer—Spotlight on Cancer-Associated Fibroblasts. <i>Cancers</i> , 2020, 12, 3650.	1.7	37
391	Regulatory (FoxP3+) T cells and TGF- β 2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18994.	1.6	52
392	Interrogating Cellular Communication in Cancer with Genetically Encoded Imaging Reporters. <i>Radiology Imaging Cancer</i> , 2020, 2, e190053.	0.7	5
393	Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells. <i>Cancers</i> , 2020, 12, 3181.	1.7	9
394	Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2020, 11, 598877.	2.2	133
395	Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy. <i>Chemical Communications</i> , 2020, 56, 14653-14656.	2.2	49
396	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. <i>BioDrugs</i> , 2020, 34, 749-762.	2.2	5
397	Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. <i>Science Advances</i> , 2020, 6, eaay6298.	4.7	41
398	Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature. <i>Anti-Cancer Drugs</i> , 2020, 31, 540-544.	0.7	9
399	Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma. , 2020, 8, e000584.		4
400	The Role of Antigen Spreading in the Efficacy of Immunotherapies. <i>Clinical Cancer Research</i> , 2020, 26, 4442-4447.	3.2	84
401	The advent of de novo proteins for cancer immunotherapy. <i>Current Opinion in Chemical Biology</i> , 2020, 56, 119-128.	2.8	15
402	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. <i>Drug Resistance Updates</i> , 2020, 51, 100702.	6.5	53

#	ARTICLE	IF	CITATIONS
403	<p>Immunotherapy for Medulloblastoma: Current Perspectives</p>. ImmunoTargets and Therapy, 2020, Volume 9, 57-77.	2.7	33
404	Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncolmunology, 2020, 9, 1760685.	2.1	11
405	Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 89.	3.5	157
406	Investigation of the Potential Immunological Effects of Boiling Histotripsy for Cancer Treatment. Advanced Therapeutics, 2020, 3, 1900214.	1.6	13
407	T Cell Receptor Engineered Lymphocytes for Cancer Therapy. Current Protocols in Immunology, 2020, 129, e97.	3.6	7
408	MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Medicine, 2020, 12, 45.	3.6	70
409	Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. Journal of Clinical Medicine, 2020, 9, 1508.	1.0	3
410	HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment. Journal of Cancer, 2020, 11, 4059-4072.	1.2	65
411	FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 586.	1.3	42
412	Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade. Frontiers in Immunology, 2020, 11, 1075.	2.2	36
413	Functional and metabolic targeting of natural killer cells to solid tumors. Cellular Oncology (Dordrecht), 2020, 43, 577-600.	2.1	25
414	Acquired Resistance to Immune Checkpoint Blockade Therapies. Cancers, 2020, 12, 1161.	1.7	9
415	PD<sup>L1 in squamous cell carcinoma of the oral tongue shows gender<sup>specific association with prognosis. Oral Diseases, 2020, 26, 1414-1423.	1.5	7
416	ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics, 2020, 10, 5943-5956.	4.6	76
417	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
418	CRISPR screen in mechanism and target discovery for cancer immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188378.	3.3	25
419	Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opinion on Biological Therapy, 2020, 20, 981-989.	1.4	20
420	The Soluble Isoform of CTLA-4 Correlates with Interferon-̂ Activity in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 302-304.	1.0	4

#	ARTICLE	IF	CITATIONS
421	Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. <i>Cell</i> , 2020, 181, 1643-1660.e17.	13.5	554
422	Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. <i>Genome Medicine</i> , 2020, 12, 47.	3.6	107
423	The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice. <i>Kidney Cancer</i> , 2020, 4, 121-129.	0.2	2
424	Mouse Tumor Models for Advanced Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4118.	1.8	62
425	Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188386.	3.3	67
426	Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13315.	1.7	28
427	Calreticulin couples with immune checkpoints in pancreatic cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, 36-44.	1.7	15
428	Advances in the discovery and development of selective heme-displacing IDO1 inhibitors. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1223-1232.	2.5	8
429	Outcomes of immunomodulatory and biologic therapy in people living with HIV. <i>Aids</i> , 2020, 34, 1171-1179.	1.0	7
430	Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 1512.	2.2	126
431	Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4441.	1.8	20
432	Parallel evolution of polymer chemistry and immunology: Integrating mechanistic biology with materials design. <i>Advanced Drug Delivery Reviews</i> , 2020, 156, 65-79.	6.6	15
433	Mechanisms of immune escape in the cancer immune cycle. <i>International Immunopharmacology</i> , 2020, 86, 106700.	1.7	85
434	NF- κ B and Its Role in Checkpoint Control. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3949.	1.8	45
435	Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 326-340.	1.2	10
436	Resolving the HIF paradox in pancreatic cancer. <i>Cancer Letters</i> , 2020, 489, 50-55.	3.2	9
437	Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?. <i>Cancers</i> , 2020, 12, 1583.	1.7	29
438	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1455-1489.	1.5	22

#	ARTICLE	IF	CITATIONS
439	MDSC subtypes and CD39 expression on CD8 ⁺ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. <i>European Journal of Immunology</i> , 2020, 50, 1810-1819.	1.6	57
440	Cell Death in the Origin and Treatment of Cancer. <i>Molecular Cell</i> , 2020, 78, 1045-1054.	4.5	182
441	The application of ubiquitin ligases in the PROTAC drug design. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 52, 776-790.	0.9	13
442	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	68
443	The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 899.	1.3	44
444	The Emerging Role of Exosomes in Diagnosis, Prognosis, and Therapy in Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4072.	1.8	48
445	Functional crosstalk between T cells and monocytes in cancer and atherosclerosis. <i>Journal of Leukocyte Biology</i> , 2020, 108, 297-308.	1.5	17
446	Immune checkpoint inhibitors and diabetes. <i>Practical Diabetes</i> , 2020, 37, 96-100.	0.1	1
447	Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development. <i>Current Oncology Reports</i> , 2020, 22, 70.	1.8	11
448	Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2441-2452.	2.0	13
450	Severe Immune Thrombocytopenia Induced by a Single Dose of Nivolumab in a Patient with Advanced Non-Small Cell Lung Cancer. <i>Clinics and Practice</i> , 2020, 10, 1249.	0.6	4
451	An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. <i>Nature Communications</i> , 2020, 11, 1395.	5.8	124
452	Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology. <i>Frontiers in Immunology</i> , 2020, 11, 316.	2.2	59
453	Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours. <i>Cancers</i> , 2020, 12, 683.	1.7	34
454	Decoding the Role of Interleukin-30 in the Crosstalk between Cancer and Myeloid Cells. <i>Cells</i> , 2020, 9, 615.	1.8	11
455	Immunotherapy, Inflammation and Colorectal Cancer. <i>Cells</i> , 2020, 9, 618.	1.8	167
456	Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes. <i>Immunological Reviews</i> , 2020, 295, 203-219.	2.8	25
457	Tumor Plasticity and Resistance to Immunotherapy. <i>Trends in Cancer</i> , 2020, 6, 432-441.	3.8	88

#	ARTICLE	IF	CITATIONS
458	Neurologic complications of immune checkpoint inhibitors. Expert Opinion on Drug Safety, 2020, 19, 479-488.	1.0	82
459	Deciphering UV-induced DNA Damage Responses to Prevent and Treat Skin Cancer. Photochemistry and Photobiology, 2020, 96, 478-499.	1.3	47
460	Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application. Molecular Cancer, 2020, 19, 48.	7.9	64
461	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunology, Immunotherapy, 2020, 69, 1177-1187.	2.0	66
462	Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab. Clinical Colorectal Cancer, 2020, 19, 137-140.	1.0	20
463	Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination. Molecular Therapy - Oncolytics, 2020, 16, 302-317.	2.0	7
464	Pure abscopal effect of radiotherapy in a salivary gland carcinoma: Case report, literature review, and a search for new approaches. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 226-246.	0.6	10
465	Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade. Cancer Immunology, Immunotherapy, 2020, 69, 1391-1401.	2.0	10
466	Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy. ACS Medicinal Chemistry Letters, 2020, 11, 582-588.	1.3	18
467	Checkpoint inhibitor blockade and epigenetic reprogrammability in CD8+ T-cell activation and exhaustion. , 2020, 8, 251513552090423.	1.4	2
468	Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Translational Lung Cancer Research, 2020, 9, S100-S119.	1.3	43
469	Natural killer cells and solid tumours: New therapies ahead?. Scandinavian Journal of Immunology, 2020, 91, e12878.	1.3	1
470	A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation. Cancer Immunology Research, 2020, 8, 596-608.	1.6	28
471	NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies. Cancers, 2020, 12, 817.	1.7	19
472	Tumor Microenvironment. Cancer Treatment and Research, 2020, , .	0.2	12
473	The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. BioDrugs, 2020, 34, 349-362.	2.2	33
474	Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications. Future Oncology, 2020, 16, 497-506.	1.1	16
475	Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. Frontiers in Bioengineering and Biotechnology, 2020, 8, 141.	2.0	35

#	ARTICLE	IF	CITATIONS
476	Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 49.	1.8	122
477	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 159.	2.2	73
478	Determinants of Resistance to Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1594.	1.8	39
479	Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma. <i>Urology Case Reports</i> , 2020, 32, 101128.	0.1	2
480	Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. <i>Annals of Oncology</i> , 2020, 31, 798-806.	0.6	131
481	FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 518-531.	2.5	25
482	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
483	Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure. <i>Frontiers in Immunology</i> , 2020, 11, 1350.	2.2	13
484	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. <i>Modern Pathology</i> , 2020, 33, 2221-2232.	2.9	23
485	Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. <i>Oncimmunology</i> , 2020, 9, 1748982.	2.1	23
486	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020, 26, 5086-5091.	3.2	27
488	Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity. <i>Molecular Oncology</i> , 2020, 14, 1930-1946.	2.1	21
489	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. <i>Cellular and Molecular Immunology</i> , 2020, 17, 807-821.	4.8	1,136
490	Role of DNA repair defects in predicting immunotherapy response. <i>Biomarker Research</i> , 2020, 8, 23.	2.8	47
491	Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 1184.	2.2	65
492	Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges. <i>Cancers</i> , 2020, 12, 1699.	1.7	27
493	Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. <i>PLoS ONE</i> , 2020, 15, e0235518.	1.1	26
494	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. <i>Nanomaterials</i> , 2020, 10, 1274.	1.9	26

#	ARTICLE	IF	CITATIONS
495	Absence of central tolerance in Aire-deficient mice synergizes with immune-checkpoint inhibition to enhance antitumor responses. <i>Communications Biology</i> , 2020, 3, 355.	2.0	5
496	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 1757.	1.7	17
497	IL-34, IL-36 and IL-38 in colorectal cancer—key immunoregulators of carcinogenesis. <i>Biophysical Reviews</i> , 2020, 12, 925-930.	1.5	20
498	Clinical Outcomes of Anti-programmed Death-1 Antibody-Related Pneumonitis in Patients with Non-Small Cell Lung Cancer. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 570-578.	0.3	8
499	Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. <i>European Journal of Surgical Oncology</i> , 2020, 46, e33-e39.	0.5	24
500	Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4398.	1.8	26
501	A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors. <i>Cancer Communications</i> , 2020, 40, 345-354.	3.7	30
502	Immune checkpoint inhibitor-associated celiac disease. , 2020, 8, e000958.		38
503	Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2299-2312.	5.7	94
504	Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy. <i>Trends in Immunology</i> , 2020, 41, 665-675.	2.9	42
505	Cancer immunotherapy using a polysaccharide from <i>Codium fragile</i> in a murine model. <i>Oncolmmunology</i> , 2020, 9, 1772663.	2.1	25
506	Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors. <i>Oncolmmunology</i> , 2020, 9, 1777064.	2.1	25
507	Immunotherapy combinations for the treatment of patients with solid tumors. <i>Future Oncology</i> , 2020, 16, 1715-1736.	1.1	6
508	Virus-Specific T Cell Therapies for HIV: Lessons Learned From Hematopoietic Stem Cell Transplantation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 298.	1.8	8
509	Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2020, 9, 2752-2760.	1.3	13
510	High-dose vitamin C enhances cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	143
511	Kinetics of pH-dependent interactions between PD-1 and PD-L1 immune checkpoint proteins from molecular dynamics. <i>Proteins: Structure, Function and Bioinformatics</i> , 2020, 88, 1162-1168.	1.5	4
512	Immune Checkpoint Axes Are Dysregulated in Patients With Alcoholic Hepatitis. <i>Hepatology Communications</i> , 2020, 4, 588-605.	2.0	13

#	ARTICLE	IF	CITATIONS
513	Enzyme-instructed assembly of a cholesterol conjugate promotes pro-inflammatory macrophages and induces apoptosis of cancer cells. <i>Biomaterials Science</i> , 2020, 8, 2007-2017.	2.6	10
514	Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 124.	1.1	8
515	Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. <i>OncoImmunology</i> , 2020, 9, 1722023.	2.1	37
516	Development and characterization of a novel anti-OX40 antibody for potent immune activation. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 939-950.	2.0	15
517	Cryoablation and immunotherapy of cancer. <i>Current Opinion in Biotechnology</i> , 2020, 65, 60-64.	3.3	36
518	The immune checkpoint receptor associated phosphatases SHP1 and SHP2 are not required for Î³Î±T17 cell development, activation, or skin inflammation. <i>European Journal of Immunology</i> , 2020, 50, 873-879.	1.6	10
519	Erdheim-Chester disease: An in vivo human model of M1 activation at the crossroad between chronic inflammation and cancer. <i>Journal of Leukocyte Biology</i> , 2020, 108, 591-599.	1.5	9
520	SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth. <i>Cancer Letters</i> , 2020, 476, 87-96.	3.2	20
521	Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold. <i>Biomaterials</i> , 2020, 239, 119859.	5.7	82
522	Tumor hypermetabolism confers resistance to immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 155-163.	4.3	17
523	Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 87-96.	1.5	5
524	Siglecs as Immune Cell Checkpoints in Disease. <i>Annual Review of Immunology</i> , 2020, 38, 365-395.	9.5	240
525	Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 377.	1.7	12
526	Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development. <i>Journal of Pathology</i> , 2020, 250, 420-439.	2.1	97
527	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. <i>Nature Communications</i> , 2020, 11, 661.	5.8	124
528	Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 435-446.	3.0	247
529	IL-36 in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?. <i>BMC Cancer</i> , 2020, 20, 92.	1.1	25
530	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3671-3681.	3.2	53

#	ARTICLE	IF	CITATIONS
531	Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 928-935.	2.8	32
532	Tumor Milieu Controlled by RB Tumor Suppressor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2450.	1.8	17
533	Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2531.	1.8	56
534	Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting. <i>Cancers</i> , 2020, 12, 915.	1.7	1
535	Cancer: so common and so difficult to deal with. , 2020, , 1-22.		0
536	Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. <i>Nature Medicine</i> , 2020, 26, 781-791.	15.2	75
537	Neoadjuvant immune-checkpoint blockade in resectable colon cancer. <i>Nature Medicine</i> , 2020, 26, 473-474.	15.2	12
538	Understanding the complex microenvironment in oral cancer: the contribution of the Faculty of Dentistry, University of Otago over the last 100 years. <i>Journal of the Royal Society of New Zealand</i> , 2020, 50, 15-34.	1.0	1
539	Sarcomasâ€™A barren immunological wasteland or field of opportunity for immunotherapy?. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 447-470.	0.8	4
540	Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 409-423.	1.2	15
541	Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate. , 2020, 8, e000548.		13
542	Lifting the innate immune barriers to antitumor immunity. , 2020, 8, e000695.		50
543	Immunologically modified MnFe2O4 nanoparticles to synergize photothermal therapy and immunotherapy for cancer treatment. <i>Chemical Engineering Journal</i> , 2020, 396, 125239.	6.6	59
544	Characterization of human cancer xenografts in humanized mice. , 2020, 8, e000416.		44
545	Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. <i>European Journal of Cancer</i> , 2020, 130, 182-192.	1.3	46
546	Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1083-1097.	1.4	15
547	Mechanismâ€based treatment of cancer with immune checkpoint inhibitor therapies. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1690-1702.	1.1	26
548	Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers. <i>Clinical and Experimental Immunology</i> , 2020, 200, 155-162.	1.1	12

#	ARTICLE	IF	CITATIONS
549	Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8 ⁺ T-cell functionality. , 2020, 8, e000465.		28
550	Cancer Immunoprevention: A Case Report Raising the Possibility of "Immuno-interception". Cancer Prevention Research, 2020, 13, 351-356.	0.7	7
551	Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies. Cancer Immunology Research, 2020, 8, 161-166.	1.6	48
552	Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies. Cancer Immunology Research, 2020, 8, 869-882.	1.6	16
553	Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Research, 2020, 80, 2298-2310.	0.4	87
554	CD226 ^{hi} CD8 ⁺ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy. Cancer Immunology Research, 2020, 8, 912-925.	1.6	53
555	Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib. International Journal of Molecular Sciences, 2020, 21, 2337.	1.8	10
556	Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro. International Journal of Molecular Sciences, 2020, 21, 2399.	1.8	29
557	Sex-associated molecular differences for cancer immunotherapy. Nature Communications, 2020, 11, 1779.	5.8	144
558	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases, 2021, 80, 36-48.	0.5	153
559	Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. Gut, 2021, 70, 127-138.	6.1	49
560	Diabetes mellitus induced by immune checkpoint inhibitors. Diabetes/Metabolism Research and Reviews, 2021, 37, e3366.	1.7	12
561	Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations. Oncogene, 2021, 40, 355-368.	2.6	115
562	Spontaneous Regression of Advanced Hepatocellular Carcinoma. Case Reports in Gastroenterology, 2021, 14, 491-496.	0.3	2
563	The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro. Cancer Immunology, Immunotherapy, 2021, 70, 1771-1776.	2.0	8
564	PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a ¹⁷⁷ Lu-labeled \pm PD-L1 antibody. Theranostics, 2021, 11, 304-315.	4.6	22
565	Aberrant glycosylation patterns on cancer cells: Therapeutic opportunities for glycodendrimers/metallo-dendrimers oncology. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1659.	3.3	12
566	Expression pattern of m6A regulators is significantly correlated with malignancy and antitumor immune response of breast cancer. Cancer Gene Therapy, 2021, 28, 188-196.	2.2	45

#	ARTICLE	IF	CITATIONS
567	Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 605-618.	2.3	40
568	The Anticancer Potential of T Cell Receptor-Engineered T Cells. <i>Trends in Cancer</i> , 2021, 7, 48-56.	3.8	21
569	Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 93-107.	0.9	12
570	Cell Adhesion Molecules in Plasticity and Metastasis. <i>Molecular Cancer Research</i> , 2021, 19, 25-37.	1.5	30
571	Current Microsatellite Instability Testing in Management of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, e12-e20.	1.0	32
572	Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. <i>British Journal of Cancer</i> , 2021, 124, 414-424.	2.9	38
573	A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 923-933.	2.0	52
574	Prevalence and risk factors for multimorbidity in older US patients with late-stage melanoma. <i>Journal of Geriatric Oncology</i> , 2021, 12, 388-393.	0.5	3
575	Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103172.	2.0	8
576	Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?. <i>International Journal of Cancer</i> , 2021, 149, 31-41.	2.3	23
577	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , 2021, 11, 614-625.	7.7	145
578	Recent Advances in Hyperthermia Therapy-Based Synergistic Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2004788.	11.1	233
579	Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications. <i>Arthritis and Rheumatology</i> , 2021, 73, 553-565.	2.9	21
580	The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 391-410.	2.5	20
581	Recent advances of immunotherapy for biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 527-536.	1.4	85
582	Phenylboronic-acid-based nanocomplex as a feasible delivery platform of immune checkpoint inhibitor for potent cancer immunotherapy. <i>Journal of Controlled Release</i> , 2021, 330, 1168-1177.	4.8	17
583	PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies. <i>Trends in Molecular Medicine</i> , 2021, 27, 207-219.	3.5	23
584	The Multifaceted Role of Regulatory T Cells in Breast Cancer. <i>Annual Review of Cancer Biology</i> , 2021, 5, 291-310.	2.3	24

#	ARTICLE	IF	CITATIONS
585	MS4A1 expression and function in T cells in the colorectal cancer tumor microenvironment. Cellular Immunology, 2021, 360, 104260.	1.4	23
586	Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert Review of Neurotherapeutics, 2021, 21, 205-219.	1.4	5
587	The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. Human Vaccines and Immunotherapeutics, 2021, 17, 1935-1939.	1.4	8
588	Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. British Journal of Haematology, 2021, 192, 568-576.	1.2	19
589	Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma. Cancer Immunology Research, 2021, 9, 136-146.	1.6	12
590	A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking. Biomaterials, 2021, 269, 120630.	5.7	27
591	Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment. Journal of Thrombosis and Haemostasis, 2021, 19, 161-172.	1.9	22
592	Advances in Magnetic Nanoparticle-Mediated Cancer Immune-Theranostics. Advanced Healthcare Materials, 2021, 10, e2001451.	3.9	59
593	Transient activation of tumoral DNA damage tolerance pathway coupled with immune checkpoint blockade exerts durable tumor regression in mouse melanoma. Pigment Cell and Melanoma Research, 2021, 34, 605-617.	1.5	4
594	Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy. Expert Opinion on Biological Therapy, 2021, 21, 311-322.	1.4	10
595	Allogeneic V α 19V β 2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cellular and Molecular Immunology, 2021, 18, 427-439.	4.8	122
596	Cancer Immunology and the Evolution of Immunotherapy. , 2021, , 3-29.		1
597	Immunological Features of Melanoma: Clinical Implications in the Era of New Therapies. , 2021, , 99-128.		0
598	Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer. MAbs, 2021, 13, 1857100.	2.6	12
599	Checkpoint inhibition in the fight against cancer: NK cells have some to say in it. , 2021, , 267-304.		1
600	Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy. Immune Network, 2021, 21, e23.	1.6	7
601	Hydrogels to engineer tumor microenvironments <i>in vitro</i> . Biomaterials Science, 2021, 9, 2362-2383.	2.6	17
602	Antibody-Based Molecular Imaging. , 2021, , 547-562.		0

#	ARTICLE	IF	CITATIONS
603	Theranostics: Agents for Diagnosis and Therapy. , 2021, , 655-677.		3
604	Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges. Journal of the National Cancer Institute, 2021, 113, 823-832.	3.0	31
605	Drug-Induced Neuromuscular Disorders. , 2021, , 481-491.		0
606	Comprehensive Characterization of Tumor Microenvironment Differences in Cancer between Male and Female Patients. SSRN Electronic Journal, 0, , .	0.4	0
607	Mechanisms of chemoresistance and approaches to overcome its impact in gynecologic cancers. , 2021, , 77-126.		1
608	A snapshot of the PD-1/PD-L1 pathway. Journal of Cancer, 2021, 12, 2735-2746.	1.2	105
609	Epigenetic modulation of immunotherapy and implications in head and neck cancer. Cancer and Metastasis Reviews, 2021, 40, 141-152.	2.7	21
610	Dendritic cell-based immunotherapies and their potential use in colorectal cancer immunotherapy. Journal of Microscopy and Ultrastructure, 2022, 10, 107.	0.1	4
611	Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance. International Journal of Molecular Sciences, 2021, 22, 1258.	1.8	18
612	Lysophosphatidic Acid Is an Inflammatory Lipid Exploited by Cancers for Immune Evasion via Mechanisms Similar and Distinct From CTLA-4 and PD-1. Frontiers in Immunology, 2020, 11, 531910.	2.2	10
613	Polyvinyl Alcohol Carbazate as a Polymer-Based Antitumoral Agent. Frontiers in Oncology, 2020, 10, 598394.	1.3	0
614	Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors. , 2021, 9, e001179.		2
616	The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma. Journal of Cancer, 2021, 12, 1284-1294.	1.2	51
617	Immune escape mechanisms and immunotherapy of urothelial bladder cancer. Journal of Clinical and Translational Research, 0, , .	0.3	10
618	Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models. IScience, 2021, 24, 101990.	1.9	11
619	Cancer Treatment: Preclinical & Clinical. Journal of the National Cancer Institute Monographs, 2021, 2021, 107-113.	0.9	7
620	Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer. Antibody Therapeutics, 2021, 4, 16-33.	1.2	15
621	Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells. Cancer Discovery, 2021, 11, 1100-1117.	7.7	85

#	ARTICLE	IF	CITATIONS
622	Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response. <i>Oncolimmunology</i> , 2021, 10, 1969075.	2.1	18
623	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
624	Oxygenâ€Evolving Manganese Ferrite Nanovesicles for Hypoxiaâ€Responsive Drug Delivery and Enhanced Cancer Chemoimmunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2008078.	7.8	65
625	Neoantigen landscape in metastatic nasopharyngeal carcinoma. <i>Theranostics</i> , 2021, 11, 6427-6444.	4.6	14
626	Neoadjuvant immunotherapy for elderly patients with non-small-cell lung cancer: a case report and literature review. <i>Annals of Translational Medicine</i> , 2021, 9, 182-182.	0.7	0
627	Genome editing of immune cells using CRISPR/Cas9. <i>BMB Reports</i> , 2021, 54, 59-69.	1.1	8
628	Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies. <i>Annals of Medicine</i> , 2021, 53, 762-769.	1.5	17
629	A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy. <i>Annals of Blood</i> , 0, 7, 33-33.	0.4	3
630	Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. , 2021, 9, e001698.		78
631	The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. <i>Cancers</i> , 2021, 13, 134.	1.7	67
632	Preclinical PET imaging with the novel human antibody ⁸⁹ Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues. , 2021, 9, e002025.		22
633	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 375-386.	6.3	638
634	Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. <i>JCI Insight</i> , 2021, 6, .	2.3	143
635	FcÎ³ receptorsâ€Master regulators of antibody therapy. , 2021, , 195-225.		0
636	Targeting tumor microenvironment-associated cells to reverse therapy resistance. , 2021, , 115-144.		0
637	Biological bases of cancer immunotherapy. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e3.	1.6	14
638	Immune System Efficiency in Cancer and the Microbiota Influence. <i>Pathobiology</i> , 2021, 88, 170-186.	1.9	14
639	Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics. <i>Genes</i> , 2021, 12, 159.	1.0	16

#	ARTICLE	IF	CITATIONS
640	Geographic heterogeneity in the outcomes of patients receiving immune checkpoint inhibitors for advanced solid tumors: a meta- analysis. <i>Translational Cancer Research</i> , 2021, 10, 310-326.	0.4	1
641	Digital Tools Applications to Occupational Health and Safety for People with Autism. , 2021, , 147-165.		2
642	Overcoming Therapeutic Challenges for Pancreatic Ductal with xCT Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1301, 7-24.	0.8	1
643	Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 563-580.	1.3	14
644	Branched Multipetide-combined Adjuvants Potentially Improve the Antitumor Effects on Glioblastoma. <i>Journal of Immunotherapy</i> , 2021, 44, 151-161.	1.2	2
645	Unlocking the Mystery of the Therapeutic Effects of Chinese Medicine on Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 601785.	1.6	18
646	Innovative immunotherapy targeting at PD-1/PD-L1 signaling pathway: mechanism, efficacy and safety analysis of monotherapy and combination therapies in non-small cell lung cancer (NSCLC) treatment. <i>E3S Web of Conferences</i> , 2021, 267, 02026.	0.2	0
647	Activation of NF- κ B and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	47
648	APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable. <i>Clinical Cancer Research</i> , 2021, 27, 3280-3290.	3.2	14
649	Targeting glyco-immune checkpoints for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1063-1071.	1.4	12
650	Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers. <i>PLoS ONE</i> , 2021, 16, e0247238.	1.1	20
652	Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1. <i>Nature Communications</i> , 2021, 12, 1222.	5.8	62
653	Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2497-2502.	2.0	7
654	Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. <i>Cancer</i> , 2021, 127, 1553-1567.	2.0	33
655	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. <i>Pathology</i> , 2021, 53, 141-156.	0.3	126
656	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 198-211.	5.1	773
657	Stimulation and Suppression of the Innate Immune System through Nanotechnology. <i>ACS Applied Nano Materials</i> , 2021, 4, 2303-2316.	2.4	5
658	Immunotherapy for sarcomas. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 523-537.	0.6	21

#	ARTICLE	IF	CITATIONS
659	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, Tj ETQq0 0 0 rgB.7/Overlock 10 Tf 50	10.7	107
660	CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department. <i>Clinical Toxicology</i> , 2021, 59, 376-385.	0.8	4
661	Polymeric Micelles in Cancer Immunotherapy. <i>Molecules</i> , 2021, 26, 1220.	1.7	22
662	New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries. <i>Frontiers in Immunology</i> , 2021, 12, 622064.	2.2	91
663	Targeting tumor-associated macrophages to synergize tumor immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 75.	7.1	323
664	Vaccination as Immunotherapy in Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 433-443.	0.8	8
665	FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review. <i>Clinical Cancer Research</i> , 2021, 27, 3522-3527.	3.2	32
666	Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 454-469.	1.6	23
667	Immune Infiltration Landscape in Clear Cell Renal Cell Carcinoma Implications. <i>Frontiers in Oncology</i> , 2020, 10, 491621.	1.3	15
668	The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity. <i>Frontiers in Immunology</i> , 2021, 12, 597761.	2.2	15
669	Engineering advanced logic and distributed computing in human CAR immune cells. <i>Nature Communications</i> , 2021, 12, 792.	5.8	68
670	The Immunology of Syncytialized Trophoblast. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1767.	1.8	10
671	Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation. <i>Scientific Reports</i> , 2021, 11, 4030.	1.6	10
672	Epigenetic regulation of T cell adaptive immunity. <i>Immunological Reviews</i> , 2021, 300, 9-21.	2.8	16
673	Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer. <i>Nature Communications</i> , 2021, 12, 975.	5.8	26
674	Colony-stimulating factor 3 signaling in colon and rectal cancers: Immune response and CMS classification in TCGA data. <i>PLoS ONE</i> , 2021, 16, e0247233.	1.1	13
675	Melanoma brain metastases: Biological basis and novel therapeutic strategies. <i>Experimental Dermatology</i> , 2022, 31, 31-42.	1.4	12
676	Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors. <i>British Journal of Dermatology</i> , 2021, 185, 263-271.	1.4	35

#	ARTICLE	IF	CITATIONS
677	CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer. , 2021, 9, e002045.		59
678	Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. <i>Frontiers in Immunology</i> , 2020, 11, 629722.	2.2	75
679	Nano-Oncologicals: A Tortoise Trail Reaching New Avenues. <i>Advanced Functional Materials</i> , 2021, 31, 2009860.	7.8	13
680	Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <i>European Journal of Immunology</i> , 2021, 51, 544-556.	1.6	71
681	Immune checkpoint blockade in renal cell carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 739-750.	0.8	13
682	Development of a nanobody-based immunoassay for the sensitive detection of fibrinogen-like protein 1. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1921-1929.	2.8	16
683	Non-canonical PD-1 signaling in cancer and its potential implications in clinic. , 2021, 9, e001230.		15
684	Reconsidering the Meaning of Curing Primary Breast Cancer as a Systemic Disease. <i>Frontiers in Oncology</i> , 2021, 11, 639420.	1.3	0
686	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. <i>Cardio-Oncology</i> , 2021, 7, 10.	0.8	12
687	⁶⁴ Cu/ ¹⁷⁷ Lu-DOTA-diZD, a Small-Molecule-Based Theranostic Pair for Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2705-2713.	2.9	5
688	Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy. <i>Frontiers in Immunology</i> , 2021, 12, 643291.	2.2	52
689	High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndrome. <i>PLoS ONE</i> , 2021, 16, e0248430.	1.1	5
690	Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 343-350.	1.9	75
691	Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 616629.	1.3	33
692	Decoding Tissue-Residency: Programming and Potential of Frontline Memory T Cells. <i>Cold Spring Harbor Perspectives in Biology</i> , 2021, 13, a037960.	2.3	8
693	A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 8563-8587.	1.4	8
694	Pembrolizumab-Induced Migrating Cortico-Subcortical Brain Lesions. <i>Annals of Neurology</i> , 2021, 89, 1255-1256.	2.8	1
695	Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. <i>Cancer Immunology Research</i> , 2021, 9, 554-567.	1.6	15

#	ARTICLE	IF	CITATIONS
696	Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2957-2972.	5.7	34
697	Immunotherapy in Advanced Biliary Tract Cancers. <i>Cancers</i> , 2021, 13, 1569.	1.7	19
698	Druggable genome and precision medicine in cancer: current challenges. <i>FEBS Journal</i> , 2021, 288, 6142-6158.	2.2	25
699	Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 641469.	1.8	76
700	Single-cell RNA-sequencing analyses identify heterogeneity of CD8+ T cell subpopulations and novel therapy targets in melanoma. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 105-118.	2.0	23
701	Next generation of immune checkpoint inhibitors and beyond. <i>Journal of Hematology and Oncology</i> , 2021, 14, 45.	6.9	293
702	Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/CTLA-4 directed immune checkpoint inhibition. <i>Journal of Immunological Methods</i> , 2021, 490, 112956.	0.6	5
703	Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19IL2 cures poorly immunogenic tumors when combined with radiotherapy. <i>Journal of Immunotherapy</i> , 2021, 9, e001764.		23
704	Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. <i>Journal of Immunotherapy</i> , 2021, 9, e002022.		40
705	A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer. <i>Mammalian Genome</i> , 2021, 32, 223-231.	1.0	17
706	An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity. <i>Clinical Cancer Research</i> , 2021, 27, 3167-3177.	3.2	16
707	Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. <i>Nature Communications</i> , 2021, 12, 1930.	5.8	7
708	Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. <i>Nature Communications</i> , 2021, 12, 1439.	5.8	39
709	A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker. <i>Frontiers in Immunology</i> , 2021, 12, 616881.	2.2	3
710	Inhibition of vascular adhesion protein-1 enhances the anti-tumor effects of immune checkpoint inhibitors. <i>Cancer Science</i> , 2021, 112, 1390-1401.	1.7	7
711	Characterizing the function of domain linkers in regulating the dynamics of multi-domain fusion proteins by microsecond molecular dynamics simulations and artificial intelligence. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 884-895.	1.5	2
712	Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 1162.	1.7	16
713	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	39

#	ARTICLE	IF	CITATIONS
714	InÂvivo CD8+ TÂcell CRISPR screening reveals control by Fli1 in infection and cancer. <i>Cell</i> , 2021, 184, 1262-1280.e22.	13.5	107
715	Immune checkpoint inhibitorâ€“associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	84
716	MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 640587.	1.8	67
717	Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review. <i>Bone Marrow Transplantation</i> , 2021, 56, 1784-1793.	1.3	5
718	Immune Checkpoint Inhibition as a Strategy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 86-104.	0.6	0
719	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab Â± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3926-3935.	3.2	55
720	Insulin-mediated immune dysfunction in the development of preeclampsia. <i>Journal of Molecular Medicine</i> , 2021, 99, 889-897.	1.7	10
721	Underlying mechanisms and drug intervention strategies for the tumour microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 97.	3.5	22
722	Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1501-1516.	1.0	12
723	Emerging strategies for treating metastasis. <i>Nature Cancer</i> , 2021, 2, 258-270.	5.7	71
724	Dermatologic infections in cancer patients treated with checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1528-1536.	0.6	3
725	Impact of Antiâ€“PD-1 and Antiâ€“CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e1973-e1981.	2.9	34
726	The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 634435.	2.2	27
727	Genetic and non-genetic clonal diversity in cancer evolution. <i>Nature Reviews Cancer</i> , 2021, 21, 379-392.	12.8	155
728	CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1440.	1.7	88
729	Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ. <i>Frontiers in Immunology</i> , 2021, 12, 617365.	2.2	21
730	Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1906.	1.7	6
731	Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art. <i>Current Medicinal Chemistry</i> , 2021, 28, 2234-2247.	1.2	7

#	ARTICLE	IF	CITATIONS
732	Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2021, 23, 1885-1904.	1.2	11
733	Aliphatic Polyester-Based Materials for Enhanced Cancer Immunotherapy. <i>Macromolecular Bioscience</i> , 2021, 21, e2100087.	2.1	7
734	First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1. <i>Journal of Thoracic Oncology</i> , 2021, 16, 665-676.	0.5	30
735	Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2021, 27, 4669-4679.	3.2	138
736	The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. <i>Molecules</i> , 2021, 26, 2201.	1.7	23
737	Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4712.	1.8	14
738	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , 2021, 13, 419-432.	1.0	9
739	Development of a single-chain fragment variable fused-mutant HALT-1 recombinant immunotoxin against G12V mutated KRAS colorectal cancer cells. <i>PeerJ</i> , 2021, 9, e11063.	0.9	5
740	Embracing nanomaterials' interactions with the innate immune system. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1719.	3.3	10
741	Trials and tribulations of pancreatic cancer immunotherapy. <i>Cancer Letters</i> , 2021, 504, 1-14.	3.2	37
742	The Complex Integration of T-cell Metabolism and Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 1636-1643.	7.7	64
743	Advances in Targeting Cutaneous Melanoma. <i>Cancers</i> , 2021, 13, 2090.	1.7	19
744	The Iron Curtain: Macrophages at the Interface of Systemic and Microenvironmental Iron Metabolism and Immune Response in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 614294.	2.2	20
747	Efficacy and tolerability of immunotherapy in advanced nasopharyngeal carcinoma with or without chemotherapy: a meta-analysis. <i>Brazilian Journal of Otorhinolaryngology</i> , 2021, , .	0.4	2
748	Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity. <i>Cell Reports</i> , 2021, 35, 108948.	2.9	20
749	Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, .	0.6	2
750	Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 679177.	1.3	3
751	Metabolic barriers to cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2021, 21, 785-797.	10.6	245

#	ARTICLE	IF	CITATIONS
752	Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 186.	0.4	9
753	Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. <i>Cancers</i> , 2021, 13, 2040.	1.7	4
754	Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. <i>Nature Communications</i> , 2021, 12, 2186.	5.8	86
755	Optimized polypeptide neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. <i>Genome Medicine</i> , 2021, 13, 56.	3.6	34
756	Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade. <i>Cancer Research</i> , 2021, 81, 3693-3705.	0.4	15
757	Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles. <i>Pharmaceutics</i> , 2021, 13, 525.	2.0	17
758	Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3765.	1.8	136
759	Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. <i>Brain</i> , 2021, 144, 1046-1066.	3.7	24
760	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. <i>Npj Precision Oncology</i> , 2021, 5, 33.	2.3	5
762	Evolutionary genetic algorithm identifies <i>IL2RB</i> as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. <i>NAR Genomics and Bioinformatics</i> , 2021, 3, lqab016.	1.5	10
763	Identification of combinations of somatic mutations that predict cancer survival and immunotherapy benefit. <i>NAR Cancer</i> , 2021, 3, zcab017.	1.6	2
764	Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103261.	2.0	18
765	Comprehensive analysis of tumor microenvironment and identification of an immune signature to predict the prognosis and immunotherapeutic response in lung squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 569-569.	0.7	4
766	Immunotherapy for intracranial metastatic melanoma. <i>The Cochrane Library</i> , 0, .	1.5	0
767	A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycomb target genes. <i>Nature Communications</i> , 2021, 12, 2485.	5.8	21
768	Recruiting T cells in cancer immunotherapy. <i>Science</i> , 2021, 372, 130-131.	6.0	56
769	Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	1.1	17
770	Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2021, 19, 124.	4.2	12

#	ARTICLE	IF	CITATIONS
771	Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 686556.	1.3	11
772	Post-transcriptional control of cell cytokine production: Implications for cancer therapy. <i>Immunology</i> , 2021, 164, 57-72.	2.0	3
773	Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 643255.	2.2	6
774	In vitro assessment of antitumor immune responses using tumor antigen proteins produced by transgenic silkworms. <i>Journal of Materials Science: Materials in Medicine</i> , 2021, 32, 58.	1.7	3
775	Impact of COVID-19 in patients with lymphoid malignancies. <i>World Journal of Virology</i> , 2021, 10, 97-110.	1.3	11
776	A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	9
777	High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. <i>Annals of Oncology</i> , 2021, 32, 661-672.	0.6	586
778	Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer. <i>Immunotherapy</i> , 2021, 13, 587-603.	1.0	13
779	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 3744-3756.	3.2	69
780	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 661737.	2.2	29
781	Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy. <i>BJR case Reports</i> , 2021, 7, 20200170.	0.1	1
782	Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy. <i>Cancers</i> , 2021, 13, 2543.	1.7	4
783	Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. <i>Molecular Therapy</i> , 2021, 29, 1668-1682.	3.7	33
784	Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. <i>Nature</i> , 2021, 595, 309-314.	13.7	181
785	Avances y perspectivas actuales en recursos y estrategias terapéuticas: fármacos biológicos. <i>Medicine</i> , 2021, 13, 1882-1892.	0.0	1
786	Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy. <i>Cancer Science</i> , 2021, 112, 2664-2678.	1.7	15
787	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. <i>Current Treatment Options in Oncology</i> , 2021, 22, 53.	1.3	2
788	Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 347-363.	1.5	25

#	ARTICLE	IF	CITATIONS
789	Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner. <i>Molecular Cancer Research</i> , 2021, 19, 1571-1582.	1.5	8
790	Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 633205.	2.2	42
791	Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e483-e487.	0.2	1
792	Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer. <i>Immunity</i> , 2021, 54, 1037-1054.e7.	6.6	56
793	The therapeutic landscape of hepatocellular carcinoma. <i>Med</i> , 2021, 2, 505-552.	2.2	20
794	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	2.0	48
795	Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity. <i>Cancers</i> , 2021, 13, 2735.	1.7	21
796	HLA-G/LILRBs: A Cancer Immunotherapy Challenge. <i>Trends in Cancer</i> , 2021, 7, 389-392.	3.8	34
797	Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. <i>Frontiers in Immunology</i> , 2021, 12, 663865.	2.2	17
798	Comprehensive Profiling Reveals Distinct Microenvironment and Metabolism Characterization of Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 619821.	1.1	3
799	Immunotherapy for GI Cancers. <i>Advances in Oncology</i> , 2021, 1, 283-295.	0.1	0
800	CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity. <i>Leukemia</i> , 2021, 35, 3482-3496.	3.3	22
801	Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23810.	0.9	20
802	Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. <i>BMC Pulmonary Medicine</i> , 2021, 21, 148.	0.8	20
803	CD8+ T cell metabolism in infection and cancer. <i>Nature Reviews Immunology</i> , 2021, 21, 718-738.	10.6	181
804	Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review. <i>Cancer Medicine</i> , 2021, 10, 5031-5040.	1.3	5
805	ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses. <i>Cancer Immunology Research</i> , 2021, 9, 952-966.	1.6	19
806	Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?. , 2021, 9, e002248.		35

#	ARTICLE	IF	CITATIONS
807	Post-immunotherapy imaging in lung cancer. <i>Clinical Radiology</i> , 2022, 77, 44-57.	0.5	3
808	Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study. <i>PLoS ONE</i> , 2021, 16, e0252978.	1.1	23
809	Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1117-1131.	0.6	7
810	Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5457-5464.	3.2	59
811	Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus <scp>M1</scp> via targeting regulatory T cells. <i>International Journal of Cancer</i> , 2021, 149, 1369-1384.	2.3	8
812	Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. <i>Nature Communications</i> , 2021, 12, 3424.	5.8	74
813	A phase 1b/2 study of azacitidine with PD-1 antibody avelumab in relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 3761-3771.	2.0	34
814	Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patientsâ€”Mechanism of Action and Future Concepts. <i>Cancers</i> , 2021, 13, 2836.	1.7	3
815	Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications. <i>Cancers</i> , 2021, 13, 2774.	1.7	11
816	Applications of Single-Cell Omics in Tumor Immunology. <i>Frontiers in Immunology</i> , 2021, 12, 697412.	2.2	21
817	Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy. <i>Genes and Immunity</i> , 2021, 22, 108-119.	2.2	17
818	The relationship between gastrointestinal cancers and the microbiota. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 498-509.	3.7	25
819	Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions. <i>Cancer Science</i> , 2021, 112, 3029-3040.	1.7	11
820	Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021, 13, 2839.	1.7	31
821	Immune Aging and Immunotherapy in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7016.	1.8	30
822	Emerging Fungal Infections. <i>Infectious Disease Clinics of North America</i> , 2021, 35, 261-277.	1.9	17
823	Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients. <i>European Urology Focus</i> , 2022, 8, 748-751.	1.6	6
824	An Updated Understanding of the Role of YAP in Driving Oncogenic Responses. <i>Cancers</i> , 2021, 13, 3100.	1.7	15

#	ARTICLE	IF	CITATIONS
826	Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 684098.	1.3	41
827	Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. <i>Cancers</i> , 2021, 13, 2858.	1.7	12
828	A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 378-393.	5.7	63
829	Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. <i>Nature Communications</i> , 2021, 12, 4031.	5.8	21
830	A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2766-2778.	1.3	9
831	Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00808.	1.1	6
832	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 630-638.	0.5	23
833	Single-Cell Transcriptome Analysis Reveals the M2 Macrophages and Exhausted T Cells and Intratumoral Heterogeneity in Triple-Negative Breast Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 294-312.	0.9	7
834	Microfluidics sorting enables the isolation of an intact cellular pair complex of CD8+ T cells and antigen-presenting cells in a cognate antigen recognition-dependent manner. <i>PLoS ONE</i> , 2021, 16, e0252666.	1.1	2
835	A Pilot Study of Whether the Cold-Heat Syndrome Type is Associated with Treatment Response and Immune Status in Patients with Non-Small Cell Lung Cancer. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-11.	0.5	3
836	CTLA-4 Expression and Its Clinical Significance in Breast Cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2021, 69, 16.	1.0	19
837	Targeting Trained Innate Immunity With Nanobiologics to Treat Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1839-1850.	1.1	4
838	Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects. <i>Current Pharmaceutical Design</i> , 2021, 27, 1977-1991.	0.9	7
839	Strength and Numbers: The Role of Affinity and Avidity in the "Quality" of T Cell Tolerance. <i>Cells</i> , 2021, 10, 1530.	1.8	3
840	Immunotherapy in endometrial cancer: rationale, practice and perspectives. <i>Biomarker Research</i> , 2021, 9, 49.	2.8	53
841	Emerging Roles of Liquid-Liquid Phase Separation in Cancer: From Protein Aggregation to Immune-Associated Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 631486.	1.8	48
842	Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. <i>Clinical and Translational Medicine</i> , 2021, 11, e434.	1.7	3
843	P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas. <i>Nature Communications</i> , 2021, 12, 3615.	5.8	25

#	ARTICLE	IF	CITATIONS
844	Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	30
845	NKG2D defines tumor-reacting effector CD8 ⁺ T cells within tumor microenvironment. Cancer Science, 2021, 112, 3484-3490.	1.7	4
846	Advances in Immunotherapy for Adult Glioblastoma. Cancers, 2021, 13, 3400.	1.7	9
847	CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion. Frontiers in Oncology, 2021, 11, 668349.	1.3	79
848	Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis. Frontiers in Oncology, 2021, 11, 693321.	1.3	16
849	Immunotherapy use outside clinical trial populations: never say never?. Annals of Oncology, 2021, 32, 866-880.	0.6	22
850	A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment. Scientific Reports, 2021, 11, 15406.	1.6	12
851	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. Pharmacological Research, 2021, 169, 105643.	3.1	13
852	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nature Reviews Drug Discovery, 2022, 21, 495-508.	21.5	120
853	Prognostic Implications of Immune-Related Gene Pairs Signatures in Bladder Cancer. Journal of Oncology, 2021, 2021, 1-20.	0.6	3
854	Research status on immunotherapy trials of gastric cancer. World Journal of Clinical Cases, 2021, 9, 5782-5793.	0.3	5
855	DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduction and Targeted Therapy, 2021, 6, 254.	7.1	239
856	Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer. Cancers, 2021, 13, 3765.	1.7	7
857	Injectable Supramolecular Hydrogel for Locoregional Immune Checkpoint Blockade and Enhanced Cancer Chemo-Immunotherapy. ACS Applied Materials & Interfaces, 2021, 13, 33874-33884.	4.0	38
858	Targeting the spectrum of immune checkpoints in prostate cancer. Expert Review of Clinical Pharmacology, 2021, 14, 1253-1266.	1.3	13
860	The Cancer-Immunity Cycle in Multiple Myeloma. ImmunoTargets and Therapy, 2021, Volume 10, 247-260.	2.7	11
861	A review on applications of abatacept in systemic rheumatic diseases. International Immunopharmacology, 2021, 96, 107612.	1.7	19
862	The mechanisms of action of Plasmodium infection against cancer. Cell Communication and Signaling, 2021, 19, 74.	2.7	7

#	ARTICLE	IF	CITATIONS
863	Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8035.	1.8	30
864	Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma. <i>Cancers</i> , 2021, 13, 3676.	1.7	13
865	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	48
866	Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Current Cardiology Reports</i> , 2021, 23, 98.	1.3	34
867	Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential. <i>Frontiers in Immunology</i> , 2021, 12, 682492.	2.2	18
868	Inflammation and tumor progression: signaling pathways and targeted intervention. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 263.	7.1	739
869	Evolution of systemic treatment for advanced hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 643-653.	0.8	11
870	Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory. <i>Nature Immunology</i> , 2021, 22, 1030-1041.	7.0	63
871	Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action. <i>Communications Biology</i> , 2021, 4, 927.	2.0	2
872	Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. , 2021, 9, e002851.		12
874	Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 720125.	1.3	18
875	Sialidase-Conjugated "NanoNiche" for Efficient Immune Checkpoint Blockade Therapy. <i>ACS Applied Bio Materials</i> , 2021, 4, 5735-5741.	2.3	8
876	Pulsed focused ultrasound can improve the anti-cancer effects of immune checkpoint inhibitors in murine pancreatic cancer. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20210266.	1.5	25
877	Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 577-592.	1.6	27
878	A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor-Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy. <i>Cancers</i> , 2021, 13, 3751.	1.7	18
879	Reinforcing the Combinational Immuno-Oncotherapy of Switching "Cold" Tumor to "Hot" by Responsive Penetrating Nanogels. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 36824-36838.	4.0	24
880	Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1380-1388.	1.3	11
881	Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1739.	3.3	19

#	ARTICLE	IF	CITATIONS
882	The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer. <i>Trends in Cancer</i> , 2021, 7, 624-634.	3.8	51
883	Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
884	High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma. <i>Future Oncology</i> , 2021, 17, 2893-2905.	1.1	6
885	In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV. <i>Viruses</i> , 2021, 13, 1740.	1.5	15
886	Classification and Treatment of Diseases in the Age of Genome Medicine Based on Pathway Pathology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9418.	1.8	3
887	Pancreatic Cancer and Immunotherapy: A Clinical Overview. <i>Cancers</i> , 2021, 13, 4138.	1.7	49
888	Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	17
889	Trinity immune enhancing nanoparticles for boosting antitumor immune responses of immunogenic chemotherapy. <i>Nano Research</i> , 2022, 15, 1183-1192.	5.8	7
890	p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells. <i>Frontiers in Immunology</i> , 2021, 12, 698565.	2.2	16
891	Immunologic disparities in prostate cancer between American men of African and European descent. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103426.	2.0	3
892	Multifunctional Nanocarriers-Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2100010.	1.7	5
893	Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing. <i>BMC Cancer</i> , 2021, 21, 972.	1.1	6
895	Capturing cancer evolution using genetically engineered mouse models (GEMMs). <i>Trends in Cell Biology</i> , 2021, 31, 1007-1018.	3.6	20
896	Tumor NLRP3-Derived IL-1 β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression. <i>Frontiers in Immunology</i> , 2021, 12, 661323.	2.2	44
897	Sialic Acid Ligands of CD28 Suppress Costimulation of T Cells. <i>ACS Central Science</i> , 2021, 7, 1508-1515.	5.3	24
898	Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. <i>Cells</i> , 2021, 10, 2250.	1.8	6
899	Identification of a Costimulatory Molecule-Related Signature for Predicting Prognostic Risk in Prostate Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 666300.	1.1	12
900	Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103417.	2.0	18

#	ARTICLE	IF	CITATIONS
901	Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 772-798.	0.8	11
902	Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cellâ€‘cold solid tumors. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	40
903	Nanocages displaying SIRP gamma clusters combined with prophagocytic stimulus of phagocytes potentiate anti-tumor immunity. <i>Cancer Gene Therapy</i> , 2021, 28, 960-970.	2.2	4
904	WEE1 inhibitor and ataxia telangiectasia and RAD3â€‘related inhibitor trigger stimulator of interferon geneâ€‘dependent immune response and enhance tumor treatment efficacy through programmed deathâ€‘ligand 1 blockade. <i>Cancer Science</i> , 2021, 112, 4444-4456.	1.7	17
905	Management trends and outcomes of pineal germinoma in a multi-institutional Australian cohort. <i>Journal of Clinical Neuroscience</i> , 2021, 90, 1-7.	0.8	3
906	A structural perspective on the design of decoy immune modulators. <i>Pharmacological Research</i> , 2021, 170, 105735.	3.1	0
907	Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1. <i>ESMO Open</i> , 2021, 6, 100198.	2.0	6
908	The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer. <i>Cells</i> , 2021, 10, 2234.	1.8	10
909	Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 721333.	1.1	14
910	Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature. <i>European Urology Oncology</i> , 2022, 5, 338-346.	2.6	7
911	The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1392-1402.	0.5	12
912	Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors. <i>Biomaterials</i> , 2021, 275, 120914.	5.7	40
913	Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy. <i>Nano Today</i> , 2021, 39, 101163.	6.2	18
914	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. <i>Journal of Modern Oncology</i> , 2021, 23, 319-326.	0.1	4
915	Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 704336.	1.3	29
916	Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 312.	7.1	50
917	Imaging Features of Pulmonary Immune-related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1449-1460.	0.5	8
919	The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. <i>Cancers</i> , 2021, 13, 4683.	1.7	9

#	ARTICLE	IF	CITATIONS
920	Ectopic activation of the miR-200câ€“EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. <i>Science Translational Medicine</i> , 2021, 13, eabg4328.	5.8	8
921	Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in Î³Î± T, MAIT, and NKT Cells. <i>Cancers</i> , 2021, 13, 4647.	1.7	11
922	Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs. <i>Journal of Biological Chemistry</i> , 2021, 297, 101033.	1.6	12
923	PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 731798.	1.6	134
924	Atezolizumab: an investigational agent for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1007-1015.	1.9	2
925	At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention. <i>Cancers</i> , 2021, 13, 4852.	1.7	15
927	Checkpoint Blockade + Chemotherapy: the Right Combination for AML?. <i>Blood Cancer Discovery</i> , 2021, 2, 551-554.	2.6	2
928	Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a037895.	2.9	24
929	A costimulatory molecule-related signature in regard to evaluation of prognosis and immune features for clear cell renal cell carcinoma. <i>Cell Death Discovery</i> , 2021, 7, 252.	2.0	11
930	Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma. <i>Oncogene</i> , 2021, 40, 6130-6138.	2.6	21
931	Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 730240.	1.8	7
932	Functional Characterization of Pembrolizumab Produced in <i>Nicotiana benthamiana</i> Using a Rapid Transient Expression System. <i>Frontiers in Plant Science</i> , 2021, 12, 736299.	1.7	18
933	Current Immunotherapeutic Strategies for the Treatment of Glioblastoma. <i>Cancers</i> , 2021, 13, 4548.	1.7	16
934	Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human. <i>Cancers</i> , 2021, 13, 4553.	1.7	6
935	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4719.	1.7	7
936	An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 698199.	1.3	5
937	DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2021, 19, 274.	0.8	10
938	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. <i>Cancers</i> , 2021, 13, 4797.	1.7	12

#	ARTICLE	IF	CITATIONS
939	Sharpening up tumor microenvironment to enhance the efficacy of immune checkpoint blockade on head and neck cancer using a CpG-oligodeoxynucleotide. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	7
940	The Immune System of Mesothelioma Patients: A Window of Opportunity for Novel Immunotherapies. , 0, , .		0
941	Comprehensive Analysis of the Prognostic Value and Immune Function of Immune Checkpoints in Stomach Adenocarcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5807-5824.	0.8	7
942	Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade. <i>Cancers</i> , 2021, 13, 4616.	1.7	13
943	Novel Therapies in Oncology: An Individualized Approach. <i>AACN Advanced Critical Care</i> , 2021, 32, 315-323.	0.6	1
944	New Immunotherapeutic Approaches for Glioblastoma. <i>Journal of Immunology Research</i> , 2021, 2021, 1-19.	0.9	7
945	Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. <i>International Journal of Cancer</i> , 2022, 150, 100-111.	2.3	11
946	Quercetin inhibiting the PD-1/PD-L1 interaction for immune-enhancing cancer chemopreventive agent. <i>Phytotherapy Research</i> , 2021, 35, 6441-6451.	2.8	19
947	Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival. <i>Frontiers in Immunology</i> , 2021, 12, 694843.	2.2	4
948	Clinical Predictors of Response to Anti-PD-1 First-Line Treatment in a Single-Centre Patient Cohort: A Real-World Study. <i>Clinical Oncology</i> , 2022, 34, e18-e24.	0.6	3
949	Elevated T cell repertoire diversity is associated with progression of lung squamous cell premalignant lesions. , 2021, 9, e002647.		1
950	The promise and perils of immunotherapy. <i>Blood Advances</i> , 2021, 5, 3709-3725.	2.5	23
951	Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. <i>International Immunopharmacology</i> , 2021, 98, 107876.	1.7	15
952	Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors. <i>Human Gene Therapy</i> , 2021, 32, 1011-1028.	1.4	14
953	Deciphering Repertoire of B16 Melanoma Reactive TCRs by Immunization, In Vitro Restimulation and Sequencing of IFN γ -Secreting T Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9859.	1.8	1
954	Sorting nexin 6 interacts with Cullin3 and regulates programmed death ligand 1 expression. <i>FEBS Letters</i> , 2021, 595, 2558-2569.	1.3	3
955	Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. <i>Immunity</i> , 2021, 54, 2338-2353.e6.	6.6	111
956	Xerostomia: an immunotherapy-related adverse effect in cancer patients. <i>Supportive Care in Cancer</i> , 2022, 30, 1681-1687.	1.0	12

#	ARTICLE	IF	CITATIONS
957	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. <i>Nature Communications</i> , 2021, 12, 5606.	5.8	76
958	Advances in immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2021, 21, 139-145.	0.3	3
959	Immunotherapy for HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 361-370.	1.0	5
960	Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy. <i>Tissue Engineering and Regenerative Medicine</i> , 2022, 19, 263-280.	1.6	11
961	Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes. <i>Clinical Biochemistry</i> , 2021, 96, 13-18.	0.8	25
962	Antitumor immune response is associated with favorable survival in GEP-NEN G3. <i>Endocrine-Related Cancer</i> , 2021, 28, 683-693.	1.6	2
963	Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination. <i>Immunoinformatics</i> , 2021, 1-2, 100004.	1.2	1
964	Acute exacerbation of asthma induced by combined therapy of programmed death-1 Blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2021, 156, 122-124.	1.3	7
965	Rapid, sensitive and cost-effective determination of immune checkpoint inhibitor activity using a magnetic bead-based binding assay. <i>Journal of Immunological Methods</i> , 2021, 498, 113134.	0.6	1
966	RNA editing signatures identify melanoma patients who respond to Pembrolizumab or Nivolumab treatment. <i>Translational Oncology</i> , 2021, 14, 101197.	1.7	2
967	Review on combination strategy of immune checkpoint blockade, photodynamic therapy and nanomedicine against solid tumor. <i>Materials and Design</i> , 2021, 209, 109958.	3.3	8
968	A novel multifunctional vaccine platform with dendritic cell-targeting and pH-responsive for cancer immunotherapy: Antigen-directed biomimetic fabrication of a cabbage-like mannate-zinc-antigen hybrid microparticles. <i>Chemical Engineering Journal</i> , 2021, 426, 130867.	6.6	5
969	Nucleic acid-based immune checkpoint blockade: Progress and potential. , 2022, , 273-293.		0
970	Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome. <i>Scientific Reports</i> , 2021, 11, 1794.	1.6	3
971	Laser nanobubbles induce immunogenic cell death in breast cancer. <i>Nanoscale</i> , 2021, 13, 3644-3653.	2.8	7
972	A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets. <i>Translational Cancer Research</i> , 2021, 10, 3993-4001.	0.4	8
973	Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 343-352.	0.6	13
974	Mismatch repair mutations: Biomarker for immunotherapy in colorectal cancers. <i>Indian Journal of Cancer</i> , 2023, 60, 415-417.	0.2	2

#	ARTICLE	IF	CITATIONS
975	Infiltrating T-cell abundance combined with EMT-related gene expression as a prognostic factor of colon cancer. <i>Bioengineered</i> , 2021, 12, 2688-2701.	1.4	8
976	Full Spectrum Flow Cytometry as a Powerful Technology for Cancer Immunotherapy Research. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 612801.	1.6	52
977	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. <i>Nature Medicine</i> , 2021, 27, 152-164.	15.2	451
978	Cancer Immunotherapy. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 1-41.	0.1	0
979	Role of nano-sensitizers in radiation therapy of metastatic tumors. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100303.	0.7	7
980	Colorectal Cancer: A Model for the Study of Cancer Immunology. , 2021, , 15-30.		0
981	Immunotherapy response modeling by ex-vivo organ culture for lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2223-2234.	2.0	9
982	Quantum binding energies of checkpoint CTLA-4 in complex with the immuno-oncological drug ipilimumab. <i>Physical Chemistry Chemical Physics</i> , 2021, 23, 15620-15627.	1.3	5
983	The role of Exosomes in the Pathogenesis of Nasopharyngeal Carcinoma and the involved Clinical Application. <i>International Journal of Biological Sciences</i> , 2021, 17, 2147-2156.	2.6	14
984	Autoanticuerpos: una manifestaci3n de los eventos adversos inmunol3gicos de la inmunoterapia en c4ncer. <i>Revista Colombiana De Reumatolog4a</i> , 2021, 29, 3-3.	0.0	0
985	Theranostic Approaches Using Live Bacteria. , 2021, , 983-1004.		1
986	Targeting cancer metastasis with antibody therapeutics. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1698.	3.3	17
987	Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. <i>OncImmunology</i> , 2021, 10, 1943253.	2.1	20
988	Inhibition of Colony-Stimulating Factor-1 Receptor Enhances the Efficacy of Radiotherapy and Reduces Immune Suppression in Glioblastoma. <i>In Vivo</i> , 2021, 35, 119-129.	0.6	24
989	Noninvasive Imaging of Cancer Immunotherapy. <i>Nanotheranostics</i> , 2021, 5, 90-112.	2.7	22
990	New cytometry tools for immune monitoring during cancer immunotherapy. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 10-18.	0.7	11
991	Sono/Photodynamic Nanomedicine4Elicited Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2008061.	7.8	53
992	Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing. <i>Methods in Molecular Biology</i> , 2020, 2115, 289-325.	0.4	15

#	ARTICLE	IF	CITATIONS
993	CAR T Cell Therapy Progress and Challenges for Solid Tumors. <i>Cancer Treatment and Research</i> , 2020, 180, 297-326.	0.2	23
994	Regulatory T Cells in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1273, 105-134.	0.8	14
995	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. , 2020, 69, 1177.		1
996	Italian Clinical Practice Guidelines on Cholangiocarcinoma “ Part II: Treatment. <i>Digestive and Liver Disease</i> , 2020, 52, 1430-1442.	0.4	35
997	Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. <i>Matrix Biology</i> , 2020, 91-92, 8-18.	1.5	34
998	Tissue-resident memory CD8+ T cells in cancer immunology and immunotherapy. <i>Pharmacological Research</i> , 2020, 159, 104876.	3.1	17
999	Overcoming Resistance to Drugs Targeting KRAS Mutation. <i>Innovation(China)</i> , 2020, 1, 100035.	5.2	44
1000	CYP1B1 as a therapeutic target in cardio-oncology. <i>Clinical Science</i> , 2020, 134, 2897-2927.	1.8	21
1001	Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits. <i>International Journal of Hyperthermia</i> , 2020, 37, 18-33.	1.1	12
1002	Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. <i>OncImmunology</i> , 2020, 9, 1684714.	2.1	12
1003	The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 76-81.	0.6	7
1012	Endogenous HLA-DQ8 [±] programs superantigens (SEC/SEI) to silence toxicity and unleash a tumoricidal network with long-term melanoma survival. , 2020, 8, e001493.		3
1013	Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. <i>JCI Insight</i> , 2020, 5, .	2.3	51
1014	A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. <i>JCI Insight</i> , 2020, 5, .	2.3	25
1015	Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. <i>Journal of Clinical Investigation</i> , 2020, 130, 1595-1607.	3.9	10
1016	Killers 2.0: NK cell therapies at the forefront of cancer control. <i>Journal of Clinical Investigation</i> , 2019, 129, 3499-3510.	3.9	166
1017	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 51-61.	3.9	66
1018	Selective SIRP [±] blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. <i>Journal of Clinical Investigation</i> , 2020, 130, 6109-6123.	3.9	53

#	ARTICLE	IF	CITATIONS
1019	Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 5629-5637.	3.9	44
1020	Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097711.	1.4	20
1021	Imaging of tumour response to immunotherapy. <i>European Radiology Experimental</i> , 2020, 4, 2.	1.7	65
1022	Anticancer Drugs and the Nervous System. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 732-764.	0.4	13
1023	Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors. <i>World Journal of Oncology</i> , 2020, 11, 183-187.	0.6	4
1024	Immunodynamics of explanted human tumors for immuno-oncology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12850.	3.3	9
1025	Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer. <i>Bosnian Journal of Basic Medical Sciences</i> , 2019, 19, 227-233.	0.6	76
1026	A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties <i>in vivo</i> . <i>Oncotarget</i> , 2020, 11, 3698-3711.	0.8	8
1027	Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993.		9
1028	A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. , 2020, 3, 252-275.		18
1029	Current and future immunotherapy approaches in ovarian cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1714-1714.	0.7	19
1030	Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses. <i>Journal of Thoracic Disease</i> , 2020, 12, 4504-4509.	0.6	3
1031	Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab. <i>Internal Medicine</i> , 2020, 59, 3055-3059.	0.3	11
1032	B7-H3 Immune Checkpoint Protein in Human Cancer. <i>Current Medicinal Chemistry</i> , 2020, 27, 4062-4086.	1.2	50
1033	Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019, 14, 100-112.	0.8	16
1034	Update on tumor metabolism and patterns of response to immunotherapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 175-185.	0.4	8
1035	Development of an Immune-Related Risk Signature for Predicting Prognosis in Lung Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 978.	1.1	43
1036	Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model. <i>Frontiers in Immunology</i> , 2019, 10, 3074.	2.2	6

#	ARTICLE	IF	CITATIONS
1037	TIME Is a Great Healer—Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes. <i>Cells</i> , 2021, 10, 11.	1.8	13
1038	Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7073.	1.8	22
1039	Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. <i>World Journal of Gastroenterology</i> , 2019, 25, 6579-6606.	1.4	23
1040	Interferon- γ induced PD-L1 expression and soluble PD-L1 production in gastric cancer. <i>Oncology Letters</i> , 2020, 20, 2161-2168.	0.8	28
1041	Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress (Review). <i>Oncology Letters</i> , 2020, 20, 46.	0.8	10
1042	IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors. <i>ImmunoHorizons</i> , 2019, 3, 13-25.	0.8	66
1043	Review: The Impact of HIV Infection on Cancer Treatment with Immunotherapy. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 85-92.	0.6	2
1044	Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2020, 12, 1211-1227.	0.8	12
1045	Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1191-1199.	2.3	27
1046	A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma. <i>Cureus</i> , 2020, 12, e8395.	0.2	4
1047	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 289-308.	0.5	173
1048	Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5295.	1.7	9
1049	Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet. <i>European Journal of Immunology</i> , 2022, 52, 34-43.	1.6	2
1050	Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma. <i>Cancers</i> , 2021, 13, 5061.	1.7	9
1051	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. <i>International Urology and Nephrology</i> , 2022, 54, 47-54.	0.6	3
1052	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. <i>ESMO Open</i> , 2021, 6, 100273.	2.0	91
1053	Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy. <i>Cancer Research</i> , 2021, 81, 5745-5755.	0.4	13
1054	Ubiquitination in T-Cell Activation and Checkpoint Inhibition: New Avenues for Targeted Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10800.	1.8	17

#	ARTICLE	IF	CITATIONS
1055	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 743582.	1.6	14
1056	Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5134.	1.7	8
1057	Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	4
1058	<i>Mycobacterium tuberculosis</i> Rv3628 is an effective adjuvant via activation of dendritic cells for cancer immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 288-302.	2.0	5
1059	Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-19. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1371-1383.	1.1	12
1060	PD~L1 immunostaining: what pathologists need to know. <i>Diagnostic Pathology</i> , 2021, 16, 94.	0.9	39
1061	Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab. , 2021, 9, e002663.		9
1062	The tumor immune microenvironments of <sc>HPV</sc> ⁺ and <sc>HPV</sc> [~] head and neck cancers. <i>WIREs Mechanisms of Disease</i> , 2022, 14, e1539.	1.5	13
1063	Gut Microbiota for Esophageal Cancer: Role in Carcinogenesis and Clinical Implications. <i>Frontiers in Oncology</i> , 2021, 11, 717242.	1.3	14
1064	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction. <i>Acta Biomedica Scientifica</i> , 2021, 6, 146-159.	0.1	0
1065	Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14477-14497.	2.9	17
1066	PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. <i>Molecular Therapy</i> , 2022, 30, 579-592.	3.7	29
1067	Modulating expression of inhibitory and stimulatory immune ~checkpoints~™ using nanoparticulate-assisted nucleic acid delivery. <i>EBioMedicine</i> , 2021, 73, 103624.	2.7	6
1068	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. <i>European Journal of Cancer</i> , 2021, 158, 47-62.	1.3	32
1069	The efficacy of low-dose immunotherapy in head-and-neck cancer. <i>Cancer Research Statistics and Treatment</i> , 2019, 2, 268.	0.1	3
1071	Checkmate with Checkpoint Inhibitors: Hope and Hype. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2019, 40, 159-162.	0.1	0
1076	GASTRIC CANCER IMMUNOTHERAPY. , 2019, 18, 6-16.	0.3	0
1078	Functional In Vivo Imaging of Tumors. <i>Cancer Treatment and Research</i> , 2020, 180, 3-50.	0.2	1

#	ARTICLE	IF	CITATIONS
1079	Laparoscopic fundoplication in infants with life-threatening gastroesophageal reflux disease and associated anomalies as a predictor for surgical intervention. <i>Indian Journal of Child Health</i> , 2020, 7, 180-183.	0.2	0
1080	Immunotherapy in Pediatric Solid Tumors. <i>Clinical Pediatric Hematology-Oncology</i> , 2020, 27, 22-31.	0.0	1
1081	Preclinical imaging for targeting cancer immune evasion. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 186-193.	0.4	1
1085	The complexity of immune cell landscape in hepatocellular carcinomas with different risksâ€”reply letter. <i>Annals of Translational Medicine</i> , 2020, 8, 729-729.	0.7	0
1087	Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis. <i>Cureus</i> , 2020, 12, e8613.	0.2	7
1090	Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma. <i>Aging</i> , 2020, 12, 16514-16538.	1.4	10
1091	Infectious complications among patients with AML treated with immune checkpoint inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	3
1092	Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives. <i>Cancers</i> , 2021, 13, 5387.	1.7	11
1093	Radiotherapy driven immunomodulation of the tumor microenvironment and its impact on clinical outcomes: a promising new treatment paradigm. <i>Immunological Medicine</i> , 2021, , 1-10.	1.4	0
1094	Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 5414.	1.7	8
1095	Characterization of a library of 20 HBV-specific MHC class II-restricted T cell receptors. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 476-489.	1.8	4
1096	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11.	7.7	126
1097	Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10362-10375.	1.6	11
1098	Updates on Molecular and Biochemical Development and Progression of Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 5127.	1.0	7
1099	IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11848.	1.8	4
1101	Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation. <i>Frontiers in Pharmacology</i> , 2021, 12, 746853.	1.6	14
1102	Synergy between <i>Toxoplasma gondii</i> type IÎ³ GRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. , 2021, 9, e002970.		19
1103	Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. <i>Frontiers in Immunology</i> , 2021, 12, 770390.	2.2	44

#	ARTICLE	IF	CITATIONS
1104	Sarcoma Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 319-348.	0.8	5
1105	Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?. <i>Translational Lung Cancer Research</i> , 2020, 9, 2311-2314.	1.3	6
1106	Damage-associated molecular pattern (DAMP) activation in melanoma: investigation of the immunogenic activity of 15-deoxy, 12,14 prostamide J2. <i>Oncotarget</i> , 2020, 11, 4788-4802.	0.8	3
1108	Tumor Microenvironment: Comparison Between Primary Origin Tumors and Corresponding Brain Metastasis. , 2021, , 27-41.		0
1110	The New Era of Immunotherapy in Bile Duct Cancer Management. , 0, , .		0
1112	CHAPTER 14. Cell and Immune Therapy. <i>RSC Detection Science</i> , 2020, , 303-344.	0.0	0
1114	Primary Breast Cancer of Vulva: A Case Report with Reviewing the Literature. <i>Advances in Clinical Medicine</i> , 2020, 10, 2185-2188.	0.0	0
1115	Screening and Identification of a Novel Anti-siglec-15 Human Antibody 3F1 and the Research on Its Antitumor Activity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1116	Cancer immunotherapy. <i>Diagnostyka Laboratoryjna I Wiadomości PTDL</i> , 2020, 55, 61-66.	0.0	0
1117	Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. <i>Cancer Cell</i> , 2021, 39, 1623-1642.e20.	7.7	64
1118	Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-12.	0.9	12
1119	Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2021, 21, 1187.	1.1	6
1121	The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. <i>Current Oncology</i> , 2021, 28, 4392-4407.	0.9	4
1123	Drug-Induced Glomerulonephritis. <i>Nephrology Self-assessment Program: NephSAP</i> , 2020, 19, 151-159.	3.0	0
1125	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy. <i>Anesthesia and Analgesia</i> , 2021, 132, 374-383.	1.1	8
1127	Epigenetic mechanisms and the hallmarks of cancer: an intimate affair. <i>American Journal of Cancer Research</i> , 2020, 10, 1954-1978.	1.4	21
1128	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, .		7
1130	Immune escape mechanisms and immunotherapy of urothelial bladder cancer. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 485-500.	0.3	5

#	ARTICLE	IF	CITATIONS
1131	Canine Melanoma and Osteosarcoma Immunotherapy by Means of In Vivo DNA Electroporation. , 2021, , 277-304.		0
1132	Towards effective beta-cell replacement through understanding and targeting of the autoreactive immune response during onset of type 1 diabetes. <i>Journal of Immunology and Regenerative Medicine</i> , 2022, 15, 100057.	0.2	2
1133	Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1681-1691.	2.0	7
1134	Protein-Based Nanoparticles for the Imaging and Treatment of Solid Tumors: The Case of Ferritin Nanocages, a Narrative Review. <i>Pharmaceutics</i> , 2021, 13, 2000.	2.0	14
1135	Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 755401.	2.2	13
1136	Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 751209.	1.3	10
1137	A high OXPPOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	37
1138	Identification of a Novel Stem Cell Subtype for Clear Cell Renal Cell Carcinoma Based on Stem Cell Gene Profiling. <i>Frontiers in Oncology</i> , 2021, 11, 758989.	1.3	2
1139	Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment. <i>Cancers</i> , 2021, 13, 5911.	1.7	1
1140	Bayesian Networks to Support Decision-Making for Immune-Checkpoint Blockade in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2021, 13, 5890.	1.7	2
1141	A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 764184.	1.1	5
1142	Treatment Selection in First-line Metastatic Renal Cell Carcinomaâ€”The Contemporary Treatment Paradigm in the Age of Combination Therapy. <i>JAMA Oncology</i> , 2022, 8, 292.	3.4	35
1143	Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines. <i>Biomaterials</i> , 2022, 280, 121297.	5.7	27
1144	Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. <i>BMC Cancer</i> , 2021, 21, 1222.	1.1	28
1145	Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. <i>Nature Communications</i> , 2021, 12, 6938.	5.8	93
1146	Atezolizumab-Induced Hypothyroidism in a Patient With Pre-existing Triiodothyronine (T3) Thyrotoxicosis Due to Gravesâ€™ Disease: A Case Report and Literature Review. <i>Cureus</i> , 2021, 13, e19736.	0.2	0
1147	Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 126-141.	1.6	9
1148	HLA AND CANCER. <i>Physical and Rehabilitation Medicine Medical Rehabilitation</i> , 0, , .	0.1	0

#	ARTICLE	IF	CITATIONS
1149	Current development in adenoviral vectors for cancer immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 571-581.	2.0	7
1150	Atezolizumab-induced scleroderma: a rare complication. <i>BMJ Case Reports</i> , 2021, 14, e244968.	0.2	5
1151	Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24141.	0.9	12
1152	Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells. <i>Nature Nanotechnology</i> , 2022, 17, 98-106.	15.6	135
1153	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	12.5	643
1154	Glial Fibrillary Acidic Protein Autoimmunity. <i>Neurology</i> , 2022, 98, .	1.5	61
1155	Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1639-1639.	0.7	4
1156	Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions. <i>International Immunopharmacology</i> , 2021, 101, 108337.	1.7	3
1157	Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 113-142.	0.8	5
1158	Biomarkers of tumor microenvironment of malignant neoplasms of kidneys, urinary bladder, and prostate gland (literature review). <i>Medical Alphabet</i> , 2022, , 41-46.	0.0	0
1159	The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. <i>Immunotherapy</i> , 2022, 14, 155-167.	1.0	7
1160	Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. <i>ESMO Open</i> , 2022, 7, 100334.	2.0	10
1161	Engineered nanogels simultaneously implement HDAC inhibition and chemotherapy to boost antitumor immunity via pyroptosis. <i>Applied Materials Today</i> , 2022, 26, 101363.	2.3	9
1164	Immunotherapy for cancer. <i>South African General Practitioner</i> , 2021, 2, 89-91.	0.0	0
1165	Perspective on the Immunotherapy of Gastric Cancer. , 2021, , 89-102.		0
1166	Phase Ib/II trial of Ibrutinib and Nivolumab in Patients with Advanced Refractory Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2021, 5, 181-187.	0.2	1
1167	Eosinophils and melanoma: Implications for immunotherapy. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 192-202.	1.5	5
1168	Chemokine Receptor-Targeted Therapies: Special Case for CCR8. <i>Cancers</i> , 2022, 14, 511.	1.7	16

#	ARTICLE	IF	CITATIONS
1169	Vibration properties of immune-oncological drugs. <i>Journal of Raman Spectroscopy</i> , 2022, 53, 715-723.	1.2	1
1170	Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. , 2022, 10, e003551.		19
1171	Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 808964.	2.2	53
1172	Systemic Immune Dysregulation Correlates With Clinical Features of Early Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 754138.	2.2	6
1173	A Novel Immune-Related ceRNA Network and Relative Potential Therapeutic Drug Prediction in ccRCC. <i>Frontiers in Genetics</i> , 2021, 12, 755706.	1.1	5
1174	Sex Differences in Immunity. <i>Annual Review of Immunology</i> , 2022, 40, 75-94.	9.5	47
1175	Identification and Validation of Angiogenesis-Related Gene Expression for Predicting Prognosis in Patients With Ovarian Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 783666.	1.3	6
1176	Identification of the Association Between Toll-Like Receptors and T-Cell Activation in Takayasu's Arteritis. <i>Frontiers in Immunology</i> , 2021, 12, 792901.	2.2	3
1177	Therapeutic Efficacy of an Oncolytic Influenza Virus Carrying an Antibody Against Programmed Cell Death 1 in Hepatocellular Carcinoma. <i>Human Gene Therapy</i> , 2022, 33, 309-317.	1.4	3
1178	Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 208-218.	3.7	105
1179	Complement System: An Immunotherapy Target in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 810993.	2.2	16
1181	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 820.	1.8	15
1182	Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. , 2022, 10, e003392.		34
1183	Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 785091.	2.2	73
1184	Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function. <i>Frontiers in Immunology</i> , 2021, 12, 816658.	2.2	5
1185	PD-L1 Expression in Monocytes Correlates with Bacterial Burden and Treatment Outcomes in Active Pulmonary Tuberculosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1619.	1.8	5
1186	Bioinspired Lipoproteins of Furoxans Oxaliplatin Remodel Physical Barriers in Tumor to Potentiate T-Cell Infiltration. <i>Advanced Materials</i> , 2022, 34, e2110614.	11.1	19
1187	The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 488.	1.8	31

#	ARTICLE	IF	CITATIONS
1188	Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?. <i>Cancers</i> , 2022, 14, 440.	1.7	20
1189	Emerging strategies for biomaterial-assisted cancer immunotherapy. <i>Korean Journal of Chemical Engineering</i> , 2022, 39, 227-240.	1.2	1
1190	Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias. <i>Cells</i> , 2022, 11, 139.	1.8	6
1191	Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2022, 28, 368-377.	3.2	40
1192	Expression and Prognostic Value of CD80 and CD86 in the Tumor Microenvironment of Newly Diagnosed Glioblastoma. <i>Canadian Journal of Neurological Sciences</i> , 2023, 50, 234-242.	0.3	3
1194	TCR-T Immunotherapy: The Challenges and Solutions. <i>Frontiers in Oncology</i> , 2021, 11, 794183.	1.3	36
1195	Keep a Little Fire Burning—The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1289.	1.8	2
1196	Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead. <i>Frontiers in Oncology</i> , 2022, 12, 789728.	1.3	2
1197	ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. <i>Developmental Cell</i> , 2022, 57, 329-343.e7.	3.1	42
1198	Predicting treatment outcomes using ¹⁸ F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	1.4	7
1199	Systematic Elucidation of the Aneuploidy Landscape and Identification of Aneuploidy Driver Genes in Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 723466.	1.8	3
1200	Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?. <i>Cancers</i> , 2022, 14, 482.	1.7	21
1201	Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1133.	1.8	31
1202	Vectorized Treg-depleting $\hat{I}\pm$ CTLA-4 elicits antigen cross-presentation and CD8 ⁺ T cell immunity to reject "cold" tumors. , 2022, 10, e003488.		14
1203	Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 638.	1.7	16
1204	Immune checkpoint blockade in HIV. <i>EBioMedicine</i> , 2022, 76, 103840.	2.7	15
1205	Immune Checkpoint Blockade Augments Changes Within Oncolytic Virus-induced Cancer MHC-I Peptidome, Creating Novel Antitumor CD8 T Cell Reactivities. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100182.	2.5	3
1206	Engineered implantable vaccine platform for continuous antigen-specific immunomodulation. <i>Biomaterials</i> , 2022, 281, 121374.	5.7	7

#	ARTICLE	IF	CITATIONS
1207	First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. <i>Annals of Oncology</i> , 2022, 33, 488-499.	0.6	99
1208	Harder, better, faster, stronger: biochemistry and biophysics in the immunosurveillance concert. <i>Trends in Immunology</i> , 2022, 43, 96-105.	2.9	4
1209	Intravenous liposomal vaccine enhances CTL generation, but not until antigen presentation. <i>Journal of Controlled Release</i> , 2022, 343, 1-12.	4.8	11
1210	NIR-II laser-mediated photo-Fenton-like reaction via plasmonic Cu ₉ S ₈ for immunotherapy enhancement. <i>Nano Today</i> , 2022, 43, 101397.	6.2	33
1211	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
1212	Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. <i>Acta Histochemica Et Cytochemica</i> , 2022, 55, 25-35.	0.8	4
1213	Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. <i>Theranostics</i> , 2022, 12, 1999-2014.	4.6	53
1215	High-content CRISPR screening. <i>Nature Reviews Methods Primers</i> , 2022, 2, .	11.8	155
1216	Regulating trained immunity with nanomedicine. <i>Nature Reviews Materials</i> , 2022, 7, 465-481.	23.3	45
1217	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996.	4.3	15
1218	First-line nivolumab+ ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. <i>ESMO Open</i> , 2022, 7, 100394.	2.0	7
1219	Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 287-305.	12.5	155
1220	Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response. <i>Clinical Cancer Research</i> , 2022, 28, 1479-1481.	3.2	4
1221	Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 542-565.	4.3	51
1222	High-content CRISPR screening. <i>Nature Reviews Methods Primers</i> , 2022, 2, .	11.8	24
1223	Resolving the Heterogeneous Tumor-Centric Cellular Neighborhood through Multiplexed, Spatial Paracrine Interactions in the Setting of Immune Checkpoint Blockade. <i>Cancer Research Communications</i> , 2022, 2, 78-89.	0.7	2
1224	An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
1225	PD-L1 signaling in reactive astrocytes counteracts neuroinflammation and ameliorates neuronal damage after traumatic brain injury. <i>Journal of Neuroinflammation</i> , 2022, 19, 43.	3.1	21

#	ARTICLE	IF	CITATIONS
1226	Checkpoint-Inhibitoren in der Onkologie: Rheumatologische Symptome beherrschen. , 0, , .		0
1227	Recent insights into the use of immune checkpoint inhibitors in gastric cancer. Porto Biomedical Journal, 2022, 7, e162.	0.4	3
1228	Activation pathways that drive CD4 ⁺ T cells to break tolerance in autoimmune diseases*. Immunological Reviews, 2022, 307, 161-190.	2.8	19
1229	Immunotherapies for hepatocellular carcinoma. Cancer Medicine, 2022, 11, 571-591.	1.3	29
1230	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 ⁺ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, e001650.		35
1231	Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Experimental Hematology and Oncology, 2021, 10, 60.	2.0	53
1232	NIR-II Laser-Mediated Photo-Fenton-Like Reaction & Via; Plasmonic Cu & S & for Immunotherapy Enhancement. SSRN Electronic Journal, 0, , .	0.4	0
1233	Autoantibodies: A manifestation of immune related adverse events of cancer immunotherapy. Revista Colombiana De ReumatologAa (English Edition), 2022, 29, 3-8.	0.1	0
1234	Immunotherapy in the Treatment of Advanced Colorectal Cancer. , 2022, , 113-137.		0
1236	Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma. Journal of Nuclear Medicine, 2022, , jnumed.121.263151.	2.8	0
1237	Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Molecular Cancer, 2022, 21, 57.	7.9	85
1238	Immune Checkpoint Inhibitors as a Threat to the Hypothalamusâ€Pituitary Axis: A Completed Puzzle. Cancers, 2022, 14, 1057.	1.7	4
1239	The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy. Journal of Biomedical Science, 2022, 29, 12.	2.6	27
1240	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. International Journal of Clinical Oncology, 2022, 27, 695-706.	1.0	11
1241	Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials. Journal of Thoracic Oncology, 2022, 17, 758-767.	0.5	22
1242	The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer. Current Cancer Drug Targets, 2022, 22, 617-628.	0.8	3
1243	De Ritis Ratio, Neutrophil-to-Lymphocyte Ratio, and Albumin Are Significant Prognostic Factors for Survival Even After Adjusted by the Treatment Duration in Metastatic Kidney and Bladder Cancer Treated With Immune-Checkpoint Inhibitors. The Korean Journal of Urological Oncology, 2022, 20, 25-33.	0.1	0
1244	The New Era of Immunotherapy in Gastric Cancer. Cancers, 2022, 14, 1054.	1.7	68

#	ARTICLE	IF	CITATIONS
1245	Soluble Immune Checkpoints Are Dysregulated in COVID-19 and Heavy Alcohol Users With HIV Infection. <i>Frontiers in Immunology</i> , 2022, 13, 833310.	2.2	10
1246	Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinoma. <i>Cancer Cell International</i> , 2022, 22, 97.	1.8	7
1247	Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 829451.	2.2	15
1248	A case of rapidly progressive retinopathy associated with pembrolizumab immunotherapy for metastatic urothelial carcinoma. <i>Retinal Cases and Brief Reports</i> , 2022, Publish Ahead of Print, .	0.3	1
1249	Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. <i>Seminars in Cancer Biology</i> , 2022, 86, 909-922.	4.3	26
1250	Immunotherapy Associated Neurotoxicity in Pediatric Oncology. <i>Frontiers in Oncology</i> , 2022, 12, 836452.	1.3	5
1251	High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.1	10
1252	Sex dimorphism in the tumor microenvironment “ From bench to bedside and back. <i>Seminars in Cancer Biology</i> , 2022, 86, 166-179.	4.3	8
1253	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. <i>Journal of Hematology and Oncology</i> , 2022, 15, 24.	6.9	136
1254	Checkpoint-Inhibitoren beim malignen Melanom: Rheumatologische Symptome beherrschen. , 0, , .		0
1255	F-18 Fluoro-2-Deoxyglucose Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Melanoma: Normal Variants, Pitfalls, and Artifacts. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	0.7	1
1256	Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis. <i>Thyroid</i> , 2022, 32, 496-504.	2.4	15
1257	Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 801909.	2.2	4
1258	Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions. <i>Biomedicines</i> , 2022, 10, 821.	1.4	5
1259	Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1“Resistant Melanoma. <i>Cancer Immunology Research</i> , 2022, 10, 612-625.	1.6	12
1260	MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma. <i>Cell Death Discovery</i> , 2022, 8, 117.	2.0	13
1261	Basic cancer immunology for radiation oncologists. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 508-518.	0.9	2
1263	Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression. <i>Cancer Immunology Research</i> , 2022, 10, 581-596.	1.6	24

#	ARTICLE	IF	CITATIONS
1264	Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer. <i>Clinical and Experimental Immunology</i> , 2022, 209, 22-32.	1.1	14
1265	A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. <i>Nature Immunology</i> , 2022, 23, 660-670.	7.0	191
1266	Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy. <i>Clinical and Experimental Immunology</i> , 2022, 209, 64-71.	1.1	5
1267	Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression. , 2022, 10, e003721.		6
1269	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	2.2	27
1271	Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment. <i>Molecular Oncology</i> , 2022, 16, 2153-2173.	2.1	13
1272	Evoking pyroptosis with nanomaterials for cancer immunotherapy: Current boom and novel outlook. , 2022, 1, 9130001.		8
1273	Advances in the Pathomechanisms of Delayed Drug Hypersensitivity. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 357-373.	0.7	5
1274	Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. <i>Immunity</i> , 2022, 55, 512-526.e9.	6.6	118
1275	Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 137-150.	4.3	70
1276	Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage. <i>Cancers</i> , 2022, 14, 1540.	1.7	11
1277	ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study. <i>Clinical Cancer Research</i> , 2022, 28, 2517-2526.	3.2	14
1278	Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2421-2431.	2.0	9
1279	Single-Cell Profiling Reveals Heterogeneity of Primary and Lymph Node Metastatic Tumors and Immune Cell Populations and Discovers Important Prognostic Significance of CCDC43 in Oral Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 843322.	2.2	10
1280	Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. <i>Nature</i> , 2022, 603, 942-948.	13.7	156
1281	A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells. <i>Molecular Cell</i> , 2022, 82, 1123-1139.e8.	4.5	18
1282	Immunotherapy of glioblastoma: Recent advances and future prospects. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-16.	1.4	29
1283	The Microbiome: the Link to Colorectal Cancer and Research Opportunities. <i>Current Treatment Options in Oncology</i> , 2022, 23, 631.	1.3	0

#	ARTICLE	IF	CITATIONS
1284	Cellular vesicles expressing PD-1-blocking scFv reinvigorate T cell immunity against cancer. <i>Nano Research</i> , 2022, 15, 5295-5304.	5.8	11
1287	A Novel Prognostic Ferroptosis-Related lncRNA Signature Associated with Immune Landscape in Invasive Breast Cancer. <i>Disease Markers</i> , 2022, 2022, 1-25.	0.6	4
1288	Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3207.	1.8	7
1289	Comparison of Treatment Efficacy and Survival Outcomes Between Asian and Western Patients With Unresectable Gastric or Gastro-Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 831207.	1.3	7
1290	An anti-PD-1 and GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy. <i>Nature Cancer</i> , 2022, 3, 337-354.	5.7	41
1291	Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2022, 14, 1669.	1.7	6
1292	Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, 837547.	1.3	5
1293	Identification of molecular subtypes premised on the characteristics of immune infiltration of endometrial cancer. <i>Annals of Translational Medicine</i> , 2022, 10, 337-337.	0.7	4
1295	Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100309.	0.6	8
1296	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44.	2.7	109
1297	The Prognostic Significance of RIMKLB and Related Immune Infiltrates in Colorectal Cancers. <i>Frontiers in Genetics</i> , 2022, 13, 818994.	1.1	1
1298	Development and characterization of anti-galectin-9 antibodies that protect T cells from galectin-9-induced cell death. <i>Journal of Biological Chemistry</i> , 2022, 298, 101821.	1.6	16
1299	Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2022, 183, 114177.	6.6	67
1300	First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions. <i>Immunotherapy</i> , 2022, 14, 445-457.	1.0	3
1301	Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review. <i>Academic Radiology</i> , 2022, 29, 1869-1884.	1.3	3
1302	Characterization of the immune cell infiltration landscape in lung adenocarcinoma. <i>Archives of Biochemistry and Biophysics</i> , 2022, 721, 109168.	1.4	0
1303	Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity. <i>Biomaterials</i> , 2022, 284, 121489.	5.7	33
1304	The non-cardiovascular actions of ACE. <i>Peptides</i> , 2022, 152, 170769.	1.2	5

#	ARTICLE	IF	CITATIONS
1305	Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. , 2021, 9, e002780.		15
1306	Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 788431.	2.2	12
1307	Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 205.	1.7	10
1308	Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy. <i>Annual Review of Cancer Biology</i> , 2022, 6, 17-34.	2.3	23
1309	CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 7315-7329.	1.6	15
1311	Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 5406-5429.	0.4	4
1312	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 141-153.	1.1	5
1313	Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 797880.	2.2	35
1314	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	21.5	201
1316	Magnetic nanoparticles in theranostics of malignant melanoma. <i>EJNMMI Research</i> , 2021, 11, 127.	1.1	9
1317	Mathematical modelling of tumour-immune interactions in presence of checkpoint inhibitor-based therapies for the treatment of cancer. <i>Materials Today: Proceedings</i> , 2021, , .	0.9	0
1318	GDPLichi: a DNA Damage Repair-Related Gene Classifier for Predicting Lung Adenocarcinoma Immune Checkpoint Inhibitors Response. <i>Frontiers in Oncology</i> , 2021, 11, 733533.	1.3	4
1319	MAP3K8 Is a Prognostic Biomarker and Correlated With Immune Response in Glioma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 779290.	1.6	3
1320	DISE/6mer seed toxicity-a powerful anti-cancer mechanism with implications for other diseases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 389.	3.5	11
1321	Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy. <i>Frontiers in Oncology</i> , 2021, 11, 789078.	1.3	6
1322	Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 64.	1.8	19
1323	Understanding Drug Sensitivity and Tackling Resistance in Cancer. <i>Cancer Research</i> , 2022, 82, 1448-1460.	0.4	24
1324	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. <i>Frontiers in Pharmacology</i> , 2022, 13, 835510.	1.6	10

#	ARTICLE	IF	CITATIONS
1325	Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article. <i>Current Oncology</i> , 2022, 29, 2871-2886.	0.9	24
1326	Brain coâ€delivery of firstâ€line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy. <i>Exploration</i> , 2022, 2, .	5.4	40
1327	Data-driven learning how oncogenic gene expression locally alters heterocellular networks. <i>Nature Communications</i> , 2022, 13, 1986.	5.8	3
1328	CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	105
1330	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1973-1985.	13.9	871
1331	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 862084.	2.2	18
1332	Humanized Germ-Free Mice for Investigating the Intervention Effect of Commensal Microbiome on Cancer Immunotherapy. <i>Antioxidants and Redox Signaling</i> , 2022, 37, 1291-1302.	2.5	0
1334	Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1. <i>Cancer Discovery</i> , 2022, 12, 1742-1759.	7.7	35
1335	Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy. <i>Materials and Design</i> , 2022, 217, 110656.	3.3	15
1336	Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2022, 7, 100465.	2.0	17
1377	Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma.. <i>EXCLI Journal</i> , 2022, 21, 250-268.	0.5	10
1378	Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 263-279.	2.7	11
1379	The combination of PD-1 blockade with interferon-Î± has a synergistic effect on hepatocellular carcinoma. , 2022, 19, 726-737.		28
1380	Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2117065119.	3.3	26
1381	Impact of <scp>DNA</scp> damage response defects in cancer cells on response to immunotherapy and radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 546-559.	0.9	5
1382	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. <i>Science Advances</i> , 2022, 8, eabl9171.	4.7	30
1383	HSP90 Mediates IFNÎ³-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy. <i>Cancer Research</i> , 2022, 82, 2003-2018.	0.4	12
1384	Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4).. <i>Iranian Journal of Basic Medical Sciences</i> , 2021, 24, 1264-1271.	1.0	0

#	ARTICLE	IF	CITATIONS
1385	Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task. <i>Frontiers in Endocrinology</i> , 2022, 13, 840971.	1.5	2
1386	OIP5 Is a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates. <i>Frontiers in Immunology</i> , 2022, 13, 805552.	2.2	7
1389	PPRX-1701, a Nanoparticle Formulation of 6 ⁴ ™-Bromoindirubin Acetoxime, Improves Delivery and Shows Efficacy in Immune Competent Preclinical GBM Models. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1390	Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. <i>Theranostics</i> , 2022, 12, 3719-3746.	4.6	23
1391	High Dose Local Photon Irradiation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance the Abscopal Response in a Murine Pancreatic Carcinoma Model. <i>Cancers</i> , 2022, 14, 2087.	1.7	3
1392	Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. <i>Journal of Hematology and Oncology</i> , 2022, 15, 47.	6.9	121
1393	Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 565-574.	1.1	1
1394	What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine. <i>Cancers</i> , 2022, 14, 2238.	1.7	6
1395	The Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment. <i>Cells</i> , 2022, 11, 1433.	1.8	17
1396	The mutual relationship between the host immune system and radiotherapy: stimulating the action of immune cells by irradiation. <i>International Journal of Clinical Oncology</i> , 2023, 28, 201-208.	1.0	1
1397	HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	44
1398	Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	0
1399	Regulation of intrinsic and extrinsic metabolic pathways in tumour-associated macrophages. <i>FEBS Journal</i> , 2023, 290, 3040-3058.	2.2	6
1400	Nivolumab Plus Relatlimab: First Approval. <i>Drugs</i> , 2022, 82, 925-931.	4.9	73
1401	The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy. <i>Nature Communications</i> , 2022, 13, 2506.	5.8	18
1402	Patient-derived Tumour Organoids: A Bridge between Cancer Biology and Personalised Therapy. <i>Acta Biomaterialia</i> , 2022, 146, 23-36.	4.1	10
1403	Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance. <i>Journal of Controlled Release</i> , 2022, 347, 175-182.	4.8	22
1404	Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma. <i>BMC Endocrine Disorders</i> , 2022, 22, 130.	0.9	3

#	ARTICLE	IF	CITATIONS
1405	The role of autophagy in initiation, progression, TME modification, diagnosis, and treatment of esophageal cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103702.	2.0	5
1407	Transcriptomic signatures associated with autoimmune thyroiditis in papillary thyroid carcinoma and cancer immunotherapy-induced thyroid dysfunction. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2391-2401.	1.9	0
1408	Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
1409	PD-L1 Mediates IFN γ -Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	6
1411	Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5731.	1.8	9
1412	Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics. <i>Vaccines</i> , 2022, 10, 816.	2.1	7
1413	Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UVI: long-term follow-up of three phase I clinical trials. , 2022, 10, e004345.		15
1414	Low expression of PGC-1 β and other mitochondrial biogenesis modulators in melanoma is associated with growth arrest and the induction of an immunosuppressive gene expression program dependent on MEK and IRF-1. <i>Cancer Letters</i> , 2022, 541, 215738.	3.2	3
1415	COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 176-188.	1.8	7
1417	DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	6
1418	Immune-related conditions and cancer-specific mortality among older adults with cancer in the United States. <i>International Journal of Cancer</i> , 2022, 151, 1216-1227.	2.3	4
1419	The paradox of immune checkpoint inhibition re-activating tuberculosis. <i>European Respiratory Journal</i> , 2022, 60, 2102512.	3.1	8
1420	Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.4	7
1421	Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells. <i>Cancer Research</i> , 2022, 82, 2640-2655.	0.4	13
1422	Rituximab in Refractory Myositis and Acute Neuropathy Secondary to Checkpoint Inhibitor Therapy. <i>Cureus</i> , 2022, , .	0.2	1
1423	Integrin-Linked Kinase Expression Characterizes the Immunosuppressive Tumor Microenvironment in Colorectal Cancer and Regulates PD-L1 Expression and Immune Cell Cytotoxicity. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1424	A reengineered common chain cytokine augments CD8+ T cell-dependent immunotherapy. <i>JCI Insight</i> , 2022, 7, .	2.3	2
1425	Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 641-652.	2.4	4

#	ARTICLE	IF	CITATIONS
1426	Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	7
1427	Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model. <i>Cancers</i> , 2022, 14, 2692.	1.7	11
1428	Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. <i>Cancers</i> , 2022, 14, 2687.	1.7	10
1429	Next Generation Natural Killer Cells for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	14
1430	Estimating tumor mutational burden from RNA-sequencing without a matched-normal sample. <i>Nature Communications</i> , 2022, 13, .	5.8	4
1431	Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors. <i>Advanced Science</i> , 2022, 9, .	5.6	17
1432	Emerging Therapies for Hepatocellular Carcinoma (HCC). <i>Cancers</i> , 2022, 14, 2798.	1.7	87
1434	Novel Therapies in Gynecologic Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 483-499.	1.8	4
1435	Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	15
1437	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF- β 2 blockade in HPV-unrelated head and neck cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	18
1438	Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	230
1439	Virus-Based Immuno-Oncology Models. <i>Biomedicines</i> , 2022, 10, 1441.	1.4	4
1440	Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer. <i>Journal of Investigative Medicine</i> , 2022, 70, 1329-1341.	0.7	2
1441	Immuno-reactive cancer organoid model to assess effects of the microbiome on cancer immunotherapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
1442	Identification of a novel prognostic signature for HCC and analysis of costimulatory molecule-related lncRNA AC099850.3. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1443	Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade. <i>Cancer Research</i> , 2022, 82, 2904-2917.	0.4	72
1444	Ferroptosis Inducer Improves the Efficacy of Oncolytic Virus-Mediated Cancer Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1425.	1.4	11
1445	Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. <i>OncoImmunology</i> , 2022, 11, .	2.1	6

#	ARTICLE	IF	CITATIONS
1446	Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. , 2022, 10, e004670.		21
1447	Emergence of the CD226 Axis in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1448	The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	6
1449	Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. <i>Journal of Medical Economics</i> , 2022, 25, 660-668.	1.0	3
1450	Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103746.	2.0	1
1451	Role of statins in regulating molecular pathways following traumatic brain injury: A system pharmacology study. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113304.	2.5	4
1452	Combination treatment with 17 β -estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model. <i>Cancer Letters</i> , 2022, 543, 215780.	3.2	16
1453	Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2022, 109, 102429.	3.4	30
1454	Deconstructing T Cell Clonal Dynamics in Response to Immune-Checkpoint Blockade. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1455	Immunotherapy in cancer patients with chronic hepatitis C viral infection. <i>Journal of Cancer Research and Therapeutics</i> , 2022, .	0.3	0
1456	Real World Study of Immune-Related Adverse Events Caused by PD-1 Inhibitors. <i>Advances in Clinical Medicine</i> , 2022, 12, 5913-5936.	0.0	0
1457	Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 1038-1050.	1.3	4
1458	Comprehensive analysis of the importance of PLAUR in the progression and immune microenvironment of renal clear cell carcinoma. <i>PLoS ONE</i> , 2022, 17, e0269595.	1.1	3
1459	Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer. <i>Biomedicines</i> , 2022, 10, 1539.	1.4	2
1460	Screening and Identification of a Novel Anti- α -Siglec-15 Human Antibody 3F1 and Relevant Antitumor Activity. <i>Molecular Pharmacology</i> , 2022, 102, 161-171.	1.0	1
1461	Rationale for Combing Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors in Medically Inoperable Early-Stage Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3144.	1.7	4
1462	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
1463	An in situ hydrogel-mediated chemo-immunometabolic cancer therapy. <i>Nature Communications</i> , 2022, 13, .	5.8	28

#	ARTICLE	IF	CITATIONS
1464	Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 287-300.	2.0	3
1465	HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	23
1466	Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2022, 67, 49-57.	3.2	34
1467	Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
1468	3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations. <i>Antibodies</i> , 2022, 11, 46.	1.2	3
1469	STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	44
1470	The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 800-807.e1.	2.3	5
1471	Identification of Endoplasmic Reticulum Stress-Related Subtypes, Infiltration Analysis of Tumor Microenvironment, and Construction of a Prognostic Model in Colorectal Cancer. <i>Cancers</i> , 2022, 14, 3326.	1.7	2
1472	Application of ATAC-seq in tumor-specific T cell exhaustion. <i>Cancer Gene Therapy</i> , 2023, 30, 1-10.	2.2	4
1473	Experimental investigation of skin toxicity after immune checkpoint inhibition in combination with radiation therapy. <i>Journal of Pathology</i> , 2022, 258, 189-198.	2.1	1
1474	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13
1475	Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
1476	Myocarditis Following Immune Checkpoint Inhibition With Pembrolizumab: Management in a Context of Steroid Intolerance. <i>CJC Open</i> , 2022, 4, 854-857.	0.7	2
1477	Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. <i>Journal of Immunology</i> , 2022, 209, 696-709.	0.4	14
1478	Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions. <i>Antibodies</i> , 2022, 11, 49.	1.2	8
1479	Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy. <i>Nature Communications</i> , 2022, 13, .	5.8	14
1480	PD-1 signaling facilitates activation of lymphoid tissue inducer cells by restraining fatty acid oxidation. <i>Nature Metabolism</i> , 2022, 4, 867-882.	5.1	17
1481	Visualizing β T cells by very late antigen-4-targeted positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4156-4170.	3.3	1

#	ARTICLE	IF	CITATIONS
1482	Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1483	Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1484	Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T _{reg} reduction and effector T cell activation. <i>Science Immunology</i> , 2022, 7, .	5.6	18
1485	Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. <i>Journal of Controlled Release</i> , 2022, 348, 893-910.	4.8	41
1486	Colorectal cancer immunotherapy-Recent progress and future directions. <i>Cancer Letters</i> , 2022, 545, 215816.	3.2	32
1487	The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1488	The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer. <i>Biomedicines</i> , 2022, 10, 1778.	1.4	10
1489	Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model. <i>PLoS Computational Biology</i> , 2022, 18, e1010254.	1.5	17
1490	Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Cells</i> , 2022, 11, 2249.	1.8	23
1491	The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1492	The Multi-Functional Roles of CCR7 in Human Immunology and as a Promising Therapeutic Target for Cancer Therapeutics. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	8
1493	A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1494	A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 351-369.	2.0	6
1495	Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. <i>Cells</i> , 2022, 11, 2351.	1.8	29
1496	The correlation of BTLA rs1982809 polymorphism with cancer susceptibility: A meta-analysis of 8634 participators. <i>Medicine (United States)</i> , 2022, 101, e29610.	0.4	1
1497	BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	23
1498	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	32
1499	Identification of Costimulatory Molecule-Related lncRNAs Associated With Gastric Carcinoma Progression: Evidence From Bioinformatics Analysis and Cell Experiments. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0

#	ARTICLE	IF	CITATIONS
1500	Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 449-459.	2.0	2
1501	PD-L1 testing by immunohistochemistry in Immuno-Oncology. <i>Bosnian Journal of Basic Medical Sciences</i> , 0, , .	0.6	6
1502	Comprehensive Curative Effect of Targeting PD-1 or Traditional Single-Agent Chemotherapy in Second-Line Therapy for Terminal or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	0
1503	Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects. <i>Current Medicinal Chemistry</i> , 2023, 30, 3215-3237.	1.2	3
1504	An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy. <i>MAbs</i> , 2022, 14, .	2.6	6
1505	A Shear-Thinning Biomaterial-Mediated Immune Checkpoint Blockade. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 35309-35318.	4.0	8
1506	Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8599.	1.8	10
1507	Research advances in nanomedicine applied to the systemic treatment of colorectal cancer. <i>International Journal of Cancer</i> , 2023, 152, 807-821.	2.3	5
1508	Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. <i>Cancer Cell</i> , 2022, 40, 879-894.e16.	7.7	48
1510	Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. <i>Cell Reports</i> , 2022, 40, 111256.	2.9	25
1511	Intracranial Metastatic Melanoma. , 0, , .		0
1512	Tumor microenvironmental signals reshape chromatin landscapes to limit the functional potential of exhausted T cells. <i>Science Immunology</i> , 2022, 7, .	5.6	35
1513	A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8600.	1.8	6
1514	Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis. <i>Acta OncolÃ³gica</i> , 2022, 61, 1105-1115.	0.8	7
1515	Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
1516	The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 3833.	1.7	4
1517	Siglec receptors as new immune checkpoints in cancer. <i>Molecular Aspects of Medicine</i> , 2023, 90, 101112.	2.7	25
1518	Temporally restricted activation of IFNÎ² signaling underlies response to immune checkpoint therapy in mice. <i>Nature Communications</i> , 2022, 13, .	5.8	12

#	ARTICLE	IF	CITATIONS
1519	Decoding tumor microenvironments through artificial tumor transcriptomes. <i>Cancer Cell</i> , 2022, 40, 809-811.	7.7	0
1520	NcRNA-mediated upregulation of CAMK2N1 is associated with poor prognosis and tumor immune infiltration of gastric cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1521	Image-guided intratumoral immunotherapy: Developing a clinically practical technology. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114505.	6.6	15
1522	Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancerâ€”A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
1523	The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer. <i>Modern Pathology</i> , 2022, 35, 1848-1859.	2.9	7
1524	Soluble Immune Checkpoint Protein CD27 Is a Novel Prognostic Biomarker of Hepatocellular Carcinoma Development in Hepatitis C Virusâ€”Sustained Virological Response Patients. <i>American Journal of Pathology</i> , 2022, 192, 1379-1396.	1.9	4
1525	X-box Binding Protein 1 is a Potential Immunotherapy Target in Ovarian Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
1526	Discovery of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one and 3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one derivatives as novel ENPP1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128947.	1.0	6
1527	Intercellular communication in the tumour microecosystem: Mediators and therapeutic approaches for hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166528.	1.8	8
1528	Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?. <i>Cancer Medicine</i> , 0, , .	1.3	2
1529	Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113618.	2.5	11
1530	Kinetic measurements of human CD8+ T cell cytotoxic activity in a 384-well plate format. <i>Methods in Cell Biology</i> , 2023, , 121-133.	0.5	1
1531	Tailoring peptides and peptidomimetics for targeting proteinâ€”protein interactions. , 2022, , 57-71.		1
1532	Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5150-5161.	1.9	5
1533	Inflammation as a Driver of Disease. , 2022, , .		0
1534	Arthritis Associated with Immune Checkpoint Inhibitors. <i>Rare Diseases of the Immune System</i> , 2022, , 231-242.	0.1	0
1535	Structural Basis of a Novel Agonistic Anti-OX40 Antibody. <i>Biomolecules</i> , 2022, 12, 1209.	1.8	2
1536	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 4192.	1.7	6

#	ARTICLE	IF	CITATIONS
1537	Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. <i>Journal of Thoracic Oncology</i> , 2023, 18, 79-92.	0.5	11
1538	Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	8
1539	Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	97
1540	Upregulation of PD-L1 in Senescence and Aging. <i>Molecular and Cellular Biology</i> , 2022, 42, .	1.1	24
1541	Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy. <i>Seminars in Immunopathology</i> , 2023, 45, 163-186.	2.8	14
1542	Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
1543	Immunosuppressive effects of vascular endothelial growth factor (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	11
1544	Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2022, 11, 5647.	1.0	3
1545	Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database. <i>Metabolism: Clinical and Experimental</i> , 2023, 138, 155311.	1.5	4
1546	: A case report of re-challenge of immune checkpoint inhibitors after immune-related neurological adverse events: Review of literature. <i>Medicine (United States)</i> , 2022, 101, e30236.	0.4	2
1547	Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma. <i>Journal of Medical Cases</i> , 2022, 13, 449-455.	0.4	2
1548	Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 1217-1237.	1.3	7
1549	miR-uculous new avenues for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1550	A prognostic signature of pyroptosis-related lncRNAs verified in gastric cancer samples to predict the immunotherapy and chemotherapy drug sensitivity. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
1551	Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. <i>European Journal of Endocrinology</i> , 2022, 187, G1-G21.	1.9	35
1552	The Role of Immunotherapy in Pancreatic Cancer. <i>Current Oncology</i> , 2022, 29, 6864-6892.	0.9	18
1553	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). , 2022, 10, e005413.		6
1554	Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	1

#	ARTICLE	IF	CITATIONS
1555	Blocking LAIR1 signaling in immune cells inhibits tumor development. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1556	Nucleic acidâ€“triggered tumoral immunity propagates <sc>pH</sc>â€“selective therapeutic antibodies through tumorâ€“driven epitope spreading. <i>Cancer Science</i> , 2023, 114, 321-338.	1.7	2
1557	Immuneâ€“checkpoint inhibitor therapy response evaluation using oncophysicsâ€“based mathematical models. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 0, , .	3.3	3
1558	CTLA-4-Ig internalizes CD80 in fibroblast-like synoviocytes from chronic inflammatory arthritis mouse model. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
1559	Programmed Death-Ligand 1 Expression in Lung Cancer and Paired Brain Metastasesâ€“a Single-Center Study in 190 Patients. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100413.	0.6	1
1561	The role of aging in cancer. <i>Molecular Oncology</i> , 2022, 16, 3213-3219.	2.1	7
1562	A model-informed approach to assess the risk of immune checkpoint inhibitor-induced autoimmune myocarditis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1563	Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers. <i>Cells</i> , 2022, 11, 3033.	1.8	21
1564	Construction of a tumor immune infiltration macrophage signature for predicting prognosis and immunotherapy response in liver cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
1565	Bioinformatics analysis of markers based on m⁶A related to prognosis combined with immune invasion of renal clear cell carcinoma. <i>Cell Biology International</i> , 2023, 47, 260-272.	1.4	6
1566	Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 27, 230-245.	1.8	5
1567	Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy. , 2022, 10, e005020.		12
1568	Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFÎ²) provides significant antitumor efficacy in immune checkpoint resistant models. <i>OncImmunology</i> , 2022, 11, .	2.1	6
1569	Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy. <i>Nutrition and Cancer</i> , 2023, 75, 207-218.	0.9	2
1571	Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
1572	Chemotherapy Dose Shapes the Expression of Immune-Interacting Markers on Cancer Cells. <i>Cellular and Molecular Bioengineering</i> , 2022, 15, 535-551.	1.0	3
1573	Application of genomic selection and experimental techniques to predict cell death and immunotherapeutic efficacy of ferroptosis-related CXCL2 in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1574	RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	8

#	ARTICLE	IF	CITATIONS
1575	Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity. <i>Biomaterials</i> , 2022, 290, 121841.	5.7	15
1576	Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211338.	1.4	1
1577	Molecular Pathology of Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2022, 22, 264.	0.9	6
1578	Mechanisms and Evidence on Pancreatic Cancer Prevention. , 2022, , 299-316.		0
1579	Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. <i>Biology of Sex Differences</i> , 2022, 13, .	1.8	9
1580	Synthesis and Preliminary Evaluations of [18F]fluorinated Pyridine-2- carboxamide Derivatives for Targeting PD-L1 in Cancer. <i>Current Cancer Drug Targets</i> , 2023, 23, 412-424.	0.8	1
1581	Tumor response assessment on imaging following immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
1582	Current status of immunotherapy for non-small cell lung cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
1583	Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2022, 13, .	5.8	9
1584	CD8+ T cells induce interferon-responsive oligodendrocytes and microglia in white matter aging. <i>Nature Neuroscience</i> , 2022, 25, 1446-1457.	7.1	56
1585	Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1586	ROS-Responsive Nanocomplex of aPD-L1 and Cabazitaxel Improves Intratumor Delivery and Potentiates Radiation-Mediated Antitumor Immunity. <i>Nano Letters</i> , 2022, 22, 8312-8320.	4.5	9
1587	Immune-infiltrating signature-based classification reveals CD103+CD39+ T cells associate with colorectal cancer prognosis and response to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1588	Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic. <i>Global Challenges</i> , 2023, 7, .	1.8	3
1589	Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1590	A Totipotent All-One Peptide Sequentially Blocks Immune Checkpoint and Reverses the Immunosuppressive Tumor Microenvironment. <i>Advanced Materials</i> , 2023, 35, .	11.1	10
1591	Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 797-804.	2.0	4
1592	Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
1593	Heart failure and cancer: From active exposure to passive adaption. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
1594	Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1259-1269.	1.0	0
1595	Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response. <i>Science Advances</i> , 2022, 8, .	4.7	6
1596	Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. <i>Molecular Cancer</i> , 2022, 21, .	7.9	29
1597	MARCH1 as a novel immune-related prognostic biomarker that shapes an inflamed tumor microenvironment in lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1598	Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	12
1599	IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. , 2022, 10, e005815.		4
1600	The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation. <i>Cancers</i> , 2022, 14, 5374.	1.7	4
1601	Cellular milieu in clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1602	A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood. <i>Immunological Investigations</i> , 2022, 51, 2159-2175.	1.0	3
1603	A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy. <i>Trends in Cancer</i> , 2023, 9, 6-8.	3.8	0
1604	Tumor immune checkpoints and their associated inhibitors. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 823-843.	1.3	9
1605	Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors. , 2022, 10, e005548.		9
1606	Interplay between the DNA Damage Response and Immunotherapy Response in Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13356.	1.8	3
1607	Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	49
1608	Predictive value of tumor-infiltrating lymphocytes detected by flow cytometry in colorectal cancer. <i>International Immunopharmacology</i> , 2022, 113, 109286.	1.7	2
1609	VSTM5 is a novel immune checkpoint that promotes oral tolerance of cell-mediated and antibody responses. <i>Biochemical and Biophysical Research Communications</i> , 2022, 635, 283-290.	1.0	1
1610	Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice. <i>Biomaterials</i> , 2022, 291, 121872.	5.7	12

#	ARTICLE	IF	CITATIONS
1611	Photodynamic amplified immune checkpoint-blockade therapy of self-delivery bioregulator via epigenetic reprogramming. <i>Chemical Engineering Journal</i> , 2023, 453, 139729.	6.6	2
1612	Regulation of Immune Cells by microRNAs and microRNA-Based Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 75-108.	0.8	1
1613	Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211348.	0.6	2
1614	Functional characterization and development of novel human kinase insert domain receptor chimeric antigen receptor T-cells for immunotherapy of non-small cell lung cancer. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 180, 106331.	1.9	1
1615	The role of geneâ€œambient air pollution interactions in paediatric asthma. <i>European Respiratory Review</i> , 2022, 31, 220094.	3.0	1
1616	Optimum Combination of Radiopharmaceuticalsâ€œBased Targetingâ€œTriggeringâ€œTherapy Effect and PDâ€œ1 Blockade Immunotherapy. <i>Advanced Therapeutics</i> , 2023, 6, .	1.6	1
1617	Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13696.	1.8	0
1618	Human VÎ²2 T Cells and Their Versatility for Immunotherapeutic Approaches. <i>Cells</i> , 2022, 11, 3572.	1.8	4
1619	Preclinical Study of Plasmodium Immunotherapy Combined with Radiotherapy for Solid Tumors. <i>Cells</i> , 2022, 11, 3600.	1.8	1
1620	Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13723.	1.8	0
1621	Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. <i>Immunotherapy</i> , 0, , .	1.0	0
1622	Targeting Ibrutinib to Tumor-Infiltrating T Cells with a Sialic Acid Conjugate-Modified Phospholipid Complex for Improved Tumor Immunotherapy. <i>Molecular Pharmaceutics</i> , 0, , .	2.3	1
1625	Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade. <i>Cells</i> , 2022, 11, 3534.	1.8	1
1626	Molecular Events in the Melanogenesis Cascade as Novel Melanoma-Targeted Small Molecules: Principle and Development. <i>Cancers</i> , 2022, 14, 5588.	1.7	2
1627	Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	20
1628	Improving treatment of solid cancers by nanoconjugate-mediated immune conversion of tumour cells. <i>Nature Nanotechnology</i> , 2022, 17, 1243-1244.	15.6	2
1629	Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
1630	A perspective on LILRBs and LAIR1 as immune checkpoint targets for cancer treatment. <i>Biochemical and Biophysical Research Communications</i> , 2022, 633, 64-67.	1.0	6

#	ARTICLE	IF	CITATIONS
1631	Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. <i>Annals of Oncology</i> , 2023, 34, 173-185.	0.6	8
1633	Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells. <i>Small</i> , 2023, 19, .	5.2	12
1635	Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions. <i>Frontiers in Ophthalmology</i> , 0, 2, .	0.2	3
1636	Case series of head-and-neck adenosquamous carcinoma: Role of histogenetic model in immunotherapy as a future perspective for nonconventional squamous cell carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2023, 19, 505.	0.3	1
1637	Prediction and early diagnosis of immune-checkpoint inhibitor-induced inflammatory arthritis from molecular biomarkers "Where are we now?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 162-168.	0.4	0
1638	Therapeutic targeting of dormant cancer stem cells in solid tumors. <i>Gene Reports</i> , 2023, 30, 101717.	0.4	2
1639	Spacing out dual checkpoint inhibition improves antigen-specific T cell manufacture. <i>Molecular Therapy - Methods and Clinical Development</i> , 2023, 28, 27.	1.8	0
1640	Immune Checkpoint Inhibitors. , 2022, , 233-251.		0
1641	An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis. , 2023, , 157-184.		0
1642	Immune Checkpoint Inhibitor Combination Therapy for Stage IV Pancreatic Cancer in 1 Case and Literature Review. <i>Advances in Clinical Medicine</i> , 2022, 12, 10299-10303.	0.0	0
1644	Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1645	Molecular prediction of clinical response to anti-PD-1/anti-PD-L1 immune checkpoint inhibitors: New perspectives for precision medicine and mass spectrometry-based investigations. <i>International Journal of Cancer</i> , 2023, 153, 252-264.	2.3	2
1646	Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report. <i>Translational Lung Cancer Research</i> , 2022, 11, 2346-2355.	1.3	0
1647	Immunogenic Death of Hepatocellular Carcinoma Cells in Mice Expressing Caspase-Resistant ROCK1 Is Not Replicated by ROCK Inhibitors. <i>Cancers</i> , 2022, 14, 5943.	1.7	1
1648	Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1151-1167.	1.9	3
1649	Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1650	Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGF β 2 and PD-1/PD-L1. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1187-1202.	1.9	1
1651	The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1203-1226.	1.9	1

#	ARTICLE	IF	CITATIONS
1652	From immune equilibrium to immunodynamics. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	0
1653	circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment. <i>Nature Communications</i> , 2022, 13, .	5.8	7
1654	YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. <i>Nature Cancer</i> , 0, , .	5.7	10
1655	Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1656	The origin of regulatory from the effector cells in LAG3-marked Th1 immunity against severe influenza virus infection. <i>Immunology</i> , 2023, 169, 167-184.	2.0	2
1657	The difficulty in translating the preclinical success of combined TGF β 2 and immune checkpoint inhibition to clinical trial. <i>EBioMedicine</i> , 2022, 86, 104380.	2.7	17
1659	PD-L1 expression is regulated by ATP-binding of the ERBB3 pseudokinase domain. <i>Genes and Diseases</i> , 2023, 10, 1702-1713.	1.5	1
1660	The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma. <i>American Journal of Clinical Dermatology</i> , 2023, 24, 25-40.	3.3	4
1661	Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells. , 2022, 10, e005200.		0
1662	Combination of magnetic hyperthermia and immunomodulators to drive complete tumor regression of poorly immunogenic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1493-1504.	2.0	4
1663	Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC – A systematic review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1664	Immune Checkpoint and Other Receptor-Ligand Pairs Modulating Macrophages in Cancer: Present and Prospects. <i>Cancers</i> , 2022, 14, 5963.	1.7	0
1665	Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1666	Manipulating T-cell metabolism to enhance immunotherapy in solid tumor. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1667	The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. <i>Biomedicines</i> , 2022, 10, 3154.	1.4	4
1668	Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1669	Recent Progress in Immunotherapy for Metastatic Colorectal Cancer. <i>Journal of Digestive Cancer Reports</i> , 2022, 10, 65-73.	0.0	0
1670	Age-associated remodeling of T cell immunity and metabolism. <i>Cell Metabolism</i> , 2023, 35, 36-55.	7.2	19

#	ARTICLE	IF	CITATIONS
1671	Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade. , 2022, 10, e005670.		5
1672	Effect of chromatin modifiers on the plasticity and immunogenicity of small-cell lung cancer. <i>Experimental and Molecular Medicine</i> , 2022, 54, 2118-2127.	3.2	3
1673	Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. <i>Nature Cancer</i> , 2022, 3, 1513-1533.	5.7	20
1675	Lymphangioliomyomatosis: a metastatic lung disease. <i>American Journal of Physiology - Cell Physiology</i> , 2023, 324, C320-C326.	2.1	5
1676	Macrophage Membrane-Coated Nano-Gemcitabine Promotes Lymphocyte Infiltration and Synergizes AntiPD-L1 to Restore the Tumoricidal Function. <i>ACS Nano</i> , 2023, 17, 322-336.	7.3	15
1677	Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80. <i>Journal of Biological Chemistry</i> , 2023, 299, 102769.	1.6	4
1678	Tremelimumab: First Approval. <i>Drugs</i> , 2023, 83, 93-102.	4.9	33
1679	Proteomics to study cancer immunity and improve treatment. <i>Seminars in Immunopathology</i> , 2023, 45, 241-251.	2.8	3
1680	Aptamer-Based Immunotheranostic Strategies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2023, 38, 246-255.	0.7	1
1681	Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer. <i>Oncology and Therapy</i> , 2023, 11, 49-64.	1.0	3
1682	SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRP α axis. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	8
1683	Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies. <i>Biomicrofluidics</i> , 2023, 17, .	1.2	4
1684	An Inhibitory Role for Human CD96 Endodomain in T Cell Anti-Tumor Responses. <i>Cells</i> , 2023, 12, 309.	1.8	1
1685	Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T α cells and reprogramming macrophages. <i>Immunity</i> , 2023, 56, 162-179.e6.	6.6	23
1687	Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. <i>Medical Review</i> , 2023, 2, 555-569.	0.3	6
1688	Anti-“PD-L1 Antibody and/or 17 β -Estradiol Treatment Induces Changes in the Gut Microbiome in MC38 Colon Tumor Model. <i>Cancer Research and Treatment</i> , 2023, 55, 894-909.	1.3	3
1689	Microbiome influencers of checkpoint blockade-“associated toxicity. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	13
1690	Neutrophil elastase: From mechanisms to therapeutic potential. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 355-366.	2.4	11

#	ARTICLE	IF	CITATIONS
1691	The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1692	Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism. <i>Molecules</i> , 2023, 28, 862.	1.7	4
1693	Cancer Immunotherapy Elicited by Immunogenic Cell Death Based on Smart Nanomaterials. <i>Small Methods</i> , 2023, 7, .	4.6	8
1694	Emerging Roles of Hedgehog Signaling in Cancer Immunity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1321.	1.8	8
1695	CTLA-4 inhibition facilitates follicular T _H 17 cell interaction and the production of tumor-specific antibodies. <i>International Journal of Cancer</i> , 0, , .	2.3	1
1696	Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy. <i>Cell Reports Medicine</i> , 2023, 4, 100896.	3.3	6
1697	A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma. <i>Cancer Research Communications</i> , 2023, 3, 130-139.	0.7	5
1698	The Role of Cellular Immunity and Adaptive Immunity in Pathophysiology of Brain and Spinal Cord Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 51-72.	0.8	0
1699	Application of immune checkpoint inhibitors in immunotherapy for gastric cancer. <i>Immunotherapy</i> , 2023, 15, 101-115.	1.0	2
1700	Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer. <i>Journal of Cancer Policy</i> , 2023, 35, 100382.	0.6	1
1701	Recent advancements in immunotherapy of melanoma using nanotechnology-based strategies. <i>Biomedicine and Pharmacotherapy</i> , 2023, 159, 114243.	2.5	4
1702	Analysis of C-X-C motif chemokine receptors in breast cancer: potential value in immunotherapy and prognostic prediction. <i>Annals of Translational Medicine</i> , 2022, 10, 1379-1379.	0.7	0
1703	PD-L1 Targeted Immunoliposomes with PD-L1 siRNA and HDAC Inhibitor for Anti-Lung Cancer Immunotherapy. <i>Biomedical Science Letters</i> , 2022, 28, 247-259.	0.0	0
1704	A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	0
1705	In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	25
1706	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes. <i>European Journal of Cancer</i> , 2023, 183, 174-187.	1.3	4
1707	Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review. <i>Cancers</i> , 2023, 15, 682.	1.7	2
1708	CD200 ⁺ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	12

#	ARTICLE	IF	CITATIONS
1709	Progress in the cryoablation and cryoimmunotherapy for tumor. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	9
1710	Clinical Implications of Multi-level (Scalar) Disorganisation in Cancer. , 2023, , 303-313.		0
1712	The immune system. , 2023, , 1-46.		1
1713	Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy. <i>Pharmaceutics</i> , 2023, 15, 452.	2.0	3
1714	An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382311520.	0.8	17
1716	Regulatory Immune Cells. , 2023, , 175-185.		0
1717	Research Advances in Immunotherapy for Pancreatic Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 3457-3462.	0.0	0
1718	Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers. <i>Current Oncology</i> , 2023, 30, 2127-2143.	0.9	4
1719	Integration of transcriptomics data into agent-based models of solid tumor metastasis. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 1930-1941.	1.9	0
1720	Immunotherapy as a potential treatment approach for currently incurable bone metastasis. <i>Journal of Bone and Mineral Metabolism</i> , 2023, 41, 371-379.	1.3	2
1721	Artificial Intelligence-Assisted Transcriptomic Analysis to Advance Cancer Immunotherapy. <i>Journal of Clinical Medicine</i> , 2023, 12, 1279.	1.0	0
1722	Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells. <i>Acta Biomaterialia</i> , 2023, 161, 1-36.	4.1	5
1723	Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?. <i>Immunotherapy</i> , 2023, 15, 611-618.	1.0	3
1724	Updated Immunotherapy for Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 2636.	1.0	6
1725	Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. <i>Molecular Cancer</i> , 2023, 22, .	7.9	3
1726	Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	1
1727	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. <i>International Immunopharmacology</i> , 2023, 117, 109881.	1.7	8
1728	PPRX-1701, a nanoparticle formulation of 6â€²-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models. <i>Cell Reports Medicine</i> , 2023, 4, 101019.	3.3	0

#	ARTICLE	IF	CITATIONS
1729	SMG7-AS1 as a prognostic biomarker and predictor of immunotherapy responses for skin cutaneous melanoma. <i>Genomics</i> , 2023, 115, 110614.	1.3	2
1730	Nanoassembly with self-regulated magnetic thermal therapy and controlled immuno-modulating agent release for improved immune response. <i>Journal of Controlled Release</i> , 2023, 357, 40-51.	4.8	3
1731	Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2023, 29, 238-253.	1.8	1
1732	Lactisaseibacillus rhamnosus Probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. <i>EBioMedicine</i> , 2023, 91, 104533.	2.7	11
1734	DKK1 affects survival of patients with head and neck squamous cell carcinoma by inducing resistance to radiotherapy and immunotherapy. <i>Radiotherapy and Oncology</i> , 2023, 181, 109485.	0.3	3
1735	Immunology and immunotherapy of cholangiocarcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 349-365.	8.2	28
1736	Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment. <i>Diabetic Medicine</i> , 2023, 40, .	1.2	3
1737	Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. <i>Cancer Cell</i> , 2023, 41, 272-287.e9.	7.7	64
1738	Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities. <i>Cancers</i> , 2023, 15, 866.	1.7	15
1739	The Impact of Colistin Resistance on the Activation of Innate Immunity by Lipopolysaccharide Modification. <i>Infection and Immunity</i> , 2023, 91, .	1.0	2
1740	First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. , 2023, 11, e006127.		14
1741	Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	18
1742	Ocular Myasthenia Gravis: A Current Overview. <i>Eye and Brain</i> , 0, Volume 15, 1-13.	3.8	3
1743	Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3151.	1.8	5
1744	Boosting Checkpoint Immunotherapy with Biomaterials. <i>ACS Nano</i> , 2023, 17, 3225-3258.	7.3	20
1745	Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	18
1746	IL-1 receptor-associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	5
1747	Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e242-e251.	0.9	2

#	ARTICLE	IF	CITATIONS
1748	Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. <i>Biomedicines</i> , 2023, 11, 508.	1.4	3
1749	Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines. <i>Cancers</i> , 2023, 15, 1170.	1.7	0
1750	Liver Cancer and the Curative Potential of Nanomedicine. , 2023, , 283-306.		0
1751	Implication des lymphocytes B régulateurs dans la susceptibilité aux effets indésirables auto-immuns de l'immunothérapie anti-canceruse. <i>Medecine/Sciences</i> , 2023, 39, 101-104.	0.0	0
1752	Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 135-145.	1.1	6
1753	T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
1754	Microbiota, Oxidative Stress, and Skin Cancer: An Unexpected Triangle. <i>Antioxidants</i> , 2023, 12, 546.	2.2	5
1755	Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1756	Antigen discovery for the development of cancer immunotherapy. <i>Seminars in Immunology</i> , 2023, 66, 101733.	2.7	9
1757	Advances in immune checkpoint inhibitors induced-cardiotoxicity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1758	Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. , 2023, 20, 318-340.		13
1759	The CXCL10/CXCR3 Pathway Contributes to the Synergy of Thermal Ablation and PD-1 Blockade Therapy against Tumors. <i>Cancers</i> , 2023, 15, 1427.	1.7	2
1760	Probabilistic Mixture Models Improve Calibration of Panel-derived Tumor Mutational Burden in the Context of both Tumor-normal and Tumor-only Sequencing. <i>Cancer Research Communications</i> , 2023, 3, 501-509.	0.7	1
1761	Shaping of the Clinical Landscape of Immunotherapy by PD-L1 Expression in Breast Cancer. , 2023, , 1-20.		0
1762	Deciphering the potential roles of ferroptosis in regulating tumor immunity and tumor immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
1763	The Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Outcomes of Patients Treated with Immune Checkpoint Inhibitors: a Retrospective Cohort Study. <i>Clinical Oncology</i> , 2023, , .	0.6	3
1764	Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy. <i>Oncogene</i> , 2023, 42, 1051-1057.	2.6	4
1765	PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review). <i>International Journal of Oncology</i> , 2023, 62, .	1.4	4

#	ARTICLE	IF	CITATIONS
1766	ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors. <i>NAR Cancer</i> , 2023, 5, .	1.6	0
1767	The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors. <i>Seminars in Hematology</i> , 2023, 60, 42-51.	1.8	2
1768	Raddeanin A Enhances Mitochondrial DNA- ϵ GAS/STING Axis-Mediated Antitumor Immunity by Targeting Transactive Responsive DNA-Binding Protein 43. <i>Advanced Science</i> , 2023, 10, .	5.6	8
1769	A new molecular subclassification and in silico predictions for diagnosis and prognosis of papillary thyroid cancer by alternative splicing profile. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
1770	Prominent Targets for Cancer Care: Immunotherapy Perspective. <i>Current Cancer Therapy Reviews</i> , 2023, 19, 298-317.	0.2	1
1771	Immune Gene Therapy of Cancer. , 2023, , 1-45.		0
1772	Designing temporal- and spatial-control multifunctional nanoformulations for synergistic photodynamic-enhanced tumour immunotherapy. <i>Nano Today</i> , 2023, 49, 101816.	6.2	5
1773	Identification of Genetic Alterations in Rapid Progressive Glioblastoma by Use of Whole Exome Sequencing. <i>Diagnostics</i> , 2023, 13, 1017.	1.3	3
1774	The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer-Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. <i>Cancers</i> , 2023, 15, 1642.	1.7	4
1775	Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report. <i>BMC Nephrology</i> , 2023, 24, .	0.8	4
1776	The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. <i>European Journal of Pharmacology</i> , 2023, 949, 175586.	1.7	27
1778	Association of Glycosylation-Related Genes with Different Patterns of Immune Profiles and Prognosis in Cervical Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 529.	1.1	1
1779	T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	43
1780	Anti-PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression. <i>Cancer Immunology Research</i> , 2023, 11, 763-776.	1.6	0
1782	Characterization of <i>Viscum album</i> L. Effect on Immune Escape Proteins PD-L1, PD-L2, and MHC-I in the Prostate, Colon, Lung, and Breast Cancer Cells. <i>Complementary Medicine Research</i> , 2023, 30, 386-392.	0.5	1
1783	Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	32
1784	Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
1785	Modulating T cell Phenotype and Function to Treat Hypertension. <i>Kidney360</i> , 2023, Publish Ahead of Print, .	0.9	1

#	ARTICLE	IF	CITATIONS
1787	Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 7515-7527.	1.2	3
1788	Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis. <i>Nature Communications</i> , 2023, 14, .	5.8	9
1789	Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1790	Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights. <i>Current Oncology</i> , 2023, 30, 3871-3885.	0.9	4
1791	Vestigial-like 1 (VGLL1): An ancient co-transcriptional activator linking wing, placenta, and tumor development. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188892.	3.3	3
1792	An oncolytic herpes simplex virus type 1 strain expressing a single-chain variable region antibody fragment against PD-1 and a PI3K inhibitor synergize to elicit antitumor immunity in ovarian cancer. <i>Archives of Virology</i> , 2023, 168, .	0.9	1
1793	The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma. <i>Current Oncology Reports</i> , 2023, 25, 647-657.	1.8	7
1794	The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6710.	1.8	7
1795	The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors. <i>Antibodies</i> , 2023, 12, 27.	1.2	1
1796	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. <i>Journal of Clinical Apheresis</i> , 2023, 38, 77-278.	0.7	81
1797	T-Cell Activation and Tolerance. , 2023, , 137-150.		0
1798	Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy. <i>Nature Communications</i> , 2023, 14, .	5.8	6
1799	Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects. <i>Cell Reports</i> , 2023, 42, 112364.	2.9	0
1800	Vogt-Koyanagi-Harada-like Syndrome and Electronegative Electroretinogram after Nivolumab Therapy for Metastatic Cutaneous Melanoma: A Case Report. <i>Open Ophthalmology Journal</i> , 2023, 17, .	0.1	0
1801	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. <i>Advances in Anatomic Pathology</i> , 2023, 30, 174-194.	2.4	0
1802	CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	8
1803	Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	6
1804	A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	3

#	ARTICLE	IF	CITATIONS
1806	Effects of the interactions between platelets with other cells in tumor growth and progression. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
1808	Modern T cell technologies for immunotherapy of solid tumors. <i>Medical Immunology (Russia)</i> , 2023, 25, 271-286.	0.1	0
1809	Evaluation of the immune checkpoint factors in idiopathic membranous nephropathy. <i>Molecular and Cellular Probes</i> , 2023, 69, 101914.	0.9	1
1810	Radiation therapy-activated nanoparticle and immunotherapy: The next milestone in oncology?. <i>International Review of Cell and Molecular Biology</i> , 2023, , 157-200.	1.6	2
1811	Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness. <i>Cytotherapy</i> , 2023, 25, 750-762.	0.3	4
1812	New insights on IL-36 in intestinal inflammation and colorectal cancer (Review). <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	1
1813	An integrative analysis of the single-cell transcriptome identifies DUSP4 as an exhaustion-associated gene in tumor-infiltrating CD8+ T cells. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	3
1826	Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two cases. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1838	Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	27
1869	The case for reverse engineering ketamine and psychedelics: lessons from translational oncology. A Response to Miller et al. "Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies". <i>Molecular Psychiatry</i> , 0, , .	4.1	1
1880	Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	0
1887	The landscape of T cell antigens for cancer immunotherapy. <i>Nature Cancer</i> , 2023, 4, 937-954.	5.7	14
1908	The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer. , 2023, , 1-43.		1
1914	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	5
1929	Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer. <i>BioDrugs</i> , 2023, 37, 775-791.	2.2	1
1933	Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies. <i>British Journal of Cancer</i> , 0, , .	2.9	2
1934	Therapeutic developments in pancreatic cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2024, 21, 7-24.	8.2	7
1949	Tumor Ecosystem-Directed Therapeutic Strategies. , 2023, , 675-701.		0

#	ARTICLE	IF	CITATIONS
1952	Immune checkpoints targeting dendritic cells for antibody-based modulation in cancer. <i>International Review of Cell and Molecular Biology</i> , 2024, , 145-179.	1.6	0
1975	The show and tell of cross-presentation. <i>Advances in Immunology</i> , 2023, , .	1.1	0
1986	Precision Nutrition and Cancer. , 2024, , 277-298.		1
1998	Exploring the therapeutic potential of ADC combination for triple-negative breast cancer. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	0
2000	Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	1.4	1
2002	Immunotherapy in Pancreatic Cancer. , 2023, , 97-146.		0
2003	Novel Targets in Development for Advanced Renal Cell Carcinoma. , 2023, , 309-342.		0
2028	ROS, Redox Regulation, and Anticancer Therapy. , 2023, , 311-409.		0
2034	Molecular Mechanisms of Immune Checkpoints as an Immunotherapy Tool in Hematological Malignancies. , 2024, , .		0
2038	Responsive biomaterials: optimizing control of cancer immunotherapy. <i>Nature Reviews Materials</i> , 2024, 9, 100-118.	23.3	1
2042	Immune Checkpoint Inhibition. , 2024, , 1-91.		0
2061	Mapping the single cell spatial immune landscapes of the melanoma microenvironment. <i>Clinical and Experimental Metastasis</i> , 0, , .	1.7	0
2069	THE EFFECT OF IMMUNOLOGICAL BIOMARKERS - NLR, PLR, LMR, PD-L1 ON THE SURVIVAL OF PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER. , 0, , .		0
2074	Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies. <i>Oncology and Therapy</i> , 2024, 12, 31-55.	1.0	0
2081	Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. <i>Cancer and Metastasis Reviews</i> , 2024, 43, 197-228.	2.7	0
2085	Value of 2-[18F]FDG-PET/CT in identifying immune-related adverse events in patients with melanoma or non-small cell lung cancer: a systematic scoping review. <i>Clinical and Translational Imaging</i> , 2024, 12, 187-195.	1.1	0
2107	Cancer immunotherapy. , 2024, , 79-87.		0
2108	Immune-oncological drug ipilimumab. , 2024, , 143-157.		0

#	ARTICLE	IF	CITATIONS
2112	Lung Cancer Therapy: Synergistic Potential of PD-1/PD-L1 and CTLA-4 Inhibitors. , 2024, , 297-316.		0
2119	Neurologic manifestations of autoimmunity with immune checkpoint inhibitors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 449-465.	1.0	0